

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

# **BMJ Open**

## Use of the FebriDx point-of-care assay as part of a triage algorithm for medical admissions with possible COVID-19

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-049179
Article Type:	Original research
Date Submitted by the Author:	19-Jan-2021
Complete List of Authors:	Houston, Hamish; London North West University Healthcare NHS Trust Deas, Gavin; Northwick Park Hospital Naik, Shivam; Imperial College London Shah, Kamal; Imperial College London Patel, Shiras; Imperial College London Greca Dottori, Maria; Imperial College London Tay, Michael; Imperial College London Filson, Sarah; London North West University Healthcare NHS Trust Biggin-Lamming, James; Northwick Park Hospital Ross, John; Northwick Park Hospital Vaughan, Natalie; Northwick Park Hospital Vaid, Nidhi; London North West University Healthcare NHS Trust Gopal Rao, Guduru; Northwick Park Hospital, Microbiology; Imperial College London, Amin, Amit K; Northwick Park Hospital Gupta-Wright, Ankur; University College London, Institute for Global Health John, Laurence; Northwick Park Hospital, Infectious Diseases
Keywords:	COVID-19, Molecular diagnostics < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES
	I

## SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## **BMJ Open: Original Research Article**

## <u>Title:</u>

Use of the FebriDx point-of-care assay as part of a triage algorithm for medical admissions with possible COVID-19

## <u>Authors:</u>

Hamish Houston<sup>a</sup>, Gavin Deas<sup>a</sup>, Shivam Naik<sup>b</sup>, Kamal Shah<sup>b</sup>, Shiras Patel<sup>b</sup>, Maria Greca Dottori<sup>b</sup>, Michael Tay<sup>b</sup>, Sarah Filson<sup>a</sup>, James Biggin-Lamming<sup>a</sup>, John Ross<sup>a</sup>, Natalie Vaughan<sup>a</sup>, Nidhi Vaid<sup>a</sup>, Guduru Gopal Rao<sup>a</sup>, Amit K Amin<sup>a,b</sup>, Ankur Gupta-Wright<sup>c,d,e\*</sup> Laurence John<sup>a</sup>\*

\*contributed equally

## Author Affiliations:

- a) Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, United Kingdom
- b) Imperial College School of Medicine, Imperial College London, London, United Kingdom
- c) Institute for Global Health, University College London, London, United Kingdom
- d) Ealing Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
- e) Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

## Corresponding Author:

Ankur Gupta-Wright

Institute for Global Health, University College London, Mortimer Market off Caper Street, London WC1E 6JB, United Kingdom

a.gupta-wright@ucl.ac.uk +44(0)7764607560

Word Count: 2466 (abstract 250)

Keywords: FebriDx, MxA, triage algorithm, COVID-19, diagnostics.

Running Title: FebriDx triage for COVID-19

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
10
19
20
21
22
23
24
25
26
20 27
27
28
29
30
31
32
33
34
34
35
36
37
38
39
40
40
42
43
44
45
46
47
48
49
51
52
53
54
55
56
57
58
59

60

#### ABSTRACT

<u>Objective</u>: To evaluate a triage algorithm used to identify and isolate patients with suspected COVID-19 among medical patients needing admission to hospital using simple clinical criteria and the FebriDx assay.

Design: Retrospective observational cohort

Setting: Large acute NHS hospital in London, UK

<u>Participants</u>: All medical admissions from the emergency department between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 with valid SARS-CoV-2 RT-PCR.

Interventions: Medical admissions were triaged as likely, possible or unlikely COVID-19 based on clinical criteria. Patients triaged as possible COVID-19 underwent FebriDx lateral flow assay on capillary blood, and those positive for MxA were managed as likely COVID-19.

<u>Primary Outcome measures</u>: Diagnostic accuracy (sensitivity, specificity and predictive values) of the algorithm and the FebriDx assay compared to SARS-CoV-2 RT-PCR from nasopharyngeal swabs as the reference standard.

Results: 4.0% (136) of 3,443 medical admissions had RT-PCR confirmed COVID-19. Prevalence of COVID-19 was 45.7% (80/175) in those triaged as likely, 4.1% (50/1,225) in possible and 0.3% (6/2,033) in unlikely COVID-19. Compared to SARS-CoV-2 RT-PCR, clinical triage had sensitivity of 95.6% (95%CI: 90.5% - 98.0%) and specificity of 61.5% (95%CI: 59.8% - 63.1%), whilst the triage algorithm including FebriDx had sensitivity of 92.6% (95%CI: 86.8% - 96.0%) and specificity of 86.4% (95%CI: 85.2% - 87.5%). The triage algorithm reduced the need for 2,859 patients to be admitted to isolation rooms. Ten patients missed by the algorithm had mild or asymptomatic COVID-19. Conclusions: A triage algorithm including FebriDx assay had good sensitivity and was useful to 'rule-out' COVID-19 among medical admissions to hospital.

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- Pragmatic study including a large cohort of consecutive medical admissions receiving routine • clinical care.
- A higher prevalence of COVID-19 or other respiratory pathogens might alter performance of

<text>

#### INTRODUCTION

The Coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, presents unprecedented challenges for infection prevention and control (IPC) within healthcare facilities worldwide.<sup>1</sup> Transmission may occur via respiratory droplet, fomite, or airborne routes (following aerosol-generating procedures).<sup>1–3</sup> Prolonged indoor contact increases transmission, and nosocomial transmission is common.<sup>4,5</sup> Respiratory isolation capacity (neutral or negative pressure side-rooms) is easily saturated within healthcare facilities.<sup>6</sup> Decisions to isolate patients in need of admission with suspected or possible COVID-19 must be rapid and accurate to maintain patient flow from emergency departments (EDs), yet minimise risk of nosocomial transmission.

As COVID-19 can present with non-specific symptoms, diagnostic confirmation is often sought by detection of SARS-CoV-2 ribonucleic acid (RNA) by reverse transcription-polymerase chain reaction (RT-PCR) from nasopharyngeal swab (NPS).<sup>7</sup> However, decisions about patient isolation from ED are usually required before the results of RT-PCR assays are available.<sup>8,9</sup> Even near-patient, rapid RT-PCR platforms with assay run times of 1-2 hours can be quickly overwhelmed, especially during peaks of COVID-19 incidence.<sup>10,11</sup> Multivariable diagnostic risk models, including clinical criteria and thoracic imaging, are not sufficient, but may be useful as a triage test to ration expensive or scarce point-of care assays.<sup>12,13</sup>

FebriDx (Lumos diagnostics, Sarasota, Florida, US) is a lateral flow assay that detects two host response proteins, Myxovirus resistance protein A (MxA, positive if >40ng/mL) and C-reactive protein (CRP, positive if >20mg/L) in capillary blood samples. MxA is an interferon-induced antiviral host response protein that has been studied as a biomarker to differentiate bacterial and viral respiratory infections.<sup>14–17</sup> More recently FebriDx has demonstrated a sensitivity of 93% and specificity of 86% for detecting COVID-19 compared to RT-PCR.<sup>18</sup> FebriDx could be useful as an early triage tool to identify patients with COVID-19 and help guide isolation and IPC in patients needing

#### **BMJ** Open

admission to hospital.<sup>18–21</sup> We therefore developed and implemented a COVID-19 triage algorithm, supported by FebriDx, to inform patient flow from the ED whilst awaiting RT-PCR results. Here we describe the diagnostic performance of this algorithm compared to SARS-CoV-2 RT-PCR. We also describe the impact on isolation room demand and the time to FebriDx and RT-PCR results.

#### **METHODS**

#### **Patient cohort**

We utilised data prospectively entered into a COVID-19 triage database and retrospective extraction of clinical and bed allocation data from electronic patient records and hospital IT systems at Northwick Park Hospital, a large district general hospital serving a diverse population in North-West London. Patients were included if they required admission to a medical ward from the ED between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 inclusive.

Consecutive medical admission were triaged into three categories for their likelihood of COVID-19 (unlikely, possible and likely) according to clinical features, observations and plain chest radiograph by the attending clinician based on Public Health England guidance (Table 1 and Supplementary Table 1).<sup>22</sup> Patients in the possible group underwent testing with FebriDx unless they declined, were immunosuppressed, required high dependency unit or intensive care unit (HDU/ICU) admission, had symptoms of COVID-19 for more than 10 days or had had COVID-19 previously. All patients underwent NPS testing with SARS-CoV-2 RT-PCR, with rapid RT-PCR assays being prioritised for patients in the likely group.

Patients with confirmed COVID-19 on SARS-CoV-2 RT-PCR, those triaged as likely, and those triaged as possible with a positive FebriDx or unable to have a FebriDx test were admitted to an isolation room or COVID-19 cohort area. Patients assigned to the unlikely COVID-19 group and those with a

#### **BMJ** Open

negative FebriDx test were admitted to 'non-COVID' wards whilst awaiting SARS-CoV-2 RT-PCR results. Patients were excluded from the triage system if they were under sixteen years of age or admitted under specialities other than medicine.

FebriDx testing was implemented as part of routine clinical care in response to data on assay performance for COVID-19 and an urgent clinical need.<sup>21</sup> The study was approved by the London North West University Hospitals Trust Research and Development Committee (SE20/069), and given this was a retrospective review using routinely collected clinical data, they deemed formal ethical approval was not required. Results are reported in compliance with STARD and STROBE guidelines (see supplementary materials). The FebriDx tests were purchased independently from a UK distributer, and the manufacturer had no role in the study conception, design, data analysis or manuscript preparation. Due to the retrospective nature of this study, undertaken during the COVID-19 pandemic, patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

#### **Testing procedures and definitions**

The FebriDx assay was performed as per the manufacturer's instructions at the point-of-care by ED health-care assistants following training. In brief, 5µL of capillary blood is placed on the sample window and reagents are released by pressing a button. The result is read after 10 minutes, with a positive result being the presence of a blue line in the control window and a red line in the MxA window (limit of detection 40ng/ml). The results from the CRP window were not used given all patients had laboratory CRP measurements. Staff performing FebriDx had access to clinical information but not SARS CoV-2 RT-PCR results at the time of FebriDx testing. Routine SARS CoV-2 RT-PCR was done on NPS using either the Panther Fusion SARS-CoV-2 (Hologic Inc, CA, USA), Abbott RealTime SARS-CoV-2(Abbott Park, IL, USA) or an extraction-free SARS-CoV-2 RT-PCR assay

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

developed by Health Services Laboratories (HSL), UK.<sup>23</sup> Rapid RT-PCR assays used were Xpert Xpress SARS-CoV-2 (Cepheid, CA, USA) or SAMBA II SARS-CoV-2 (Diagnostics for the Real World, CA, USA).

Patients were defined as having COVID-19 or not based on the first valid RT-PCR result up to 72 hours after admission. Patients without a valid RT-PCR result or triage status were excluded from the analysis. Vital signs, including National Early Warning Score (NEWS) were recorded on arrival to the ED. All biochemical, haematological and radiological data were from the first results within 48 hours of admission. Thoracic imaging (chest radiographs and CT) were reported and coded based upon guidelines on COVID-19 from the British Society of Thoracic Imaging (BSTI) at the time of reporting by radiologists.<sup>24</sup> Vital status is reported at the time of hospital discharge or data extraction (20<sup>th</sup> November 2020) for those who were still inpatients.

#### **Data Analysis and Statistical Methods**

We calculated the proportion of patients with confirmed COVID-19 in each triage category, and the diagnostic accuracy (sensitivity, specificity, and positive and negative predictive values with 95% confidence intervals) of both the triage algorithm overall, and the FebriDx assay in patients with possible COVID-19 compared to a SARS-CoV-2 RT-PCR reference standard. Patients with missing RT-PCR or those missing data on triaging were excluded from analysis. We also reported time to FebriDx testing and valid RT-PCR testing. We described the proportion of patients with COVID-19 who were correctly isolated, estimated the number of isolation beds made available by FebriDx testing, and described the patients with COVID-19 who were incorrectly triaged by the algorithm. Basic descriptive statistics were performed, with comparisons made using chi-squared tests for proportions, t-tests for means and Wilcoxon rank sum for medians. Logistic regression was used to compare age and sex adjusted estimates of in-hospital death in each triage group, using complete cases only. Statistical analyses were performed using Stata version 14.0 (StataCorp, LLC, College

3	
4	
5	
6	
5 6 7	
8	
9	
10	
11	
12	
13	
14	
15	
9 10 11 12 13 14 15 16 17 18 19	
17	
18	
10	
20	
20 21 22	
21	
22	
23	
23 24 25	
25	
26 27	
27	
28	
29	
30	
31 32	
2∠ 22	
33 34 35	
54 25	
35	
36 37	
3/	
38 39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

59 60 Station TX). Based on an anticipated sensitivity of 93%, a sample size of 3335 would estimate the sensitivity of the triage algorithm ±5% with alpha 0.05 and prevalence of 3%.

to beet terien only

#### RESULTS

#### **Baseline characteristics and COVID-19 diagnosis**

Between the 10<sup>th</sup> August and 4<sup>th</sup> November 2020, there were 9,645 emergency department attendances resulting in further hospital care. Of these, 3,433 (35.6%) were adult medical patients admitted for further treatment, were triaged using the algorithm based on COVID-19 status and had a valid SARS-CoV-2 RT-PCR result (figure 1). 175 (5.1%) patients were triaged as likely COVID-19, 2,033 (59.2%) patients as unlikely and 1,225 (35.7%) patients were triaged into the possible COVID-19 category. Key patient characteristics are given in Table 2.

There were several differences between the three triage groups (Table 2). The likely COVID-19 group were younger and more unwell at admission (NEWS of 5 vs 1 for patients in the unlikely group, p<0.001) and more frequently required supplemental oxygen (30.4% compared to 2.1% in the unlikely [p<0.001], and 20.4% in the possible group [p=0.003]). As expected, more patients in the likely COVID-19 group had chest radiograph changes typical for COVID-19 than in the other groups (38.3% compared to 2.3% in possible [p<0.001], and 0.3% in unlikely [p<0.001]). The possible COVID-19 group were older (median 75 years [IQR: 60 - 84]) than the other two groups and were more likely to have an elevated neutrophil count (greater than 7.5x10^9/l) than the likely or possible groups.

Overall, 136/3,443 admissions (4.0%) were diagnosed with PCR-confirmed COVID-19. Prevalence of COVID-19 was 45.7% (80/175) in likely patients, and 4.1% (50/1,225) in the possible group. Of those triaged as unlikely COVID-19, only 6/2,033 (0.3%) were SARS-CoV-2 RT-PCR positive.

#### Performance of FebriDx and triage algorithm

The overall diagnostic performance of the clinical triage algorithm compared to the gold standard of SARS-CoV-2 RT-PCR is summarised in table 3 and supplementary table 2. 958 (78.2%) patients in the

#### **BMJ** Open

possible group were tested using FebriDx (those excluded are detailed in figure 1). 13.8% (132/958) of FebriDx test results were positive for MxA, with 86.2% negative and no invalid results. The median duration of COVID-19 symptoms in patients tested by FebriDx was 2 days (IQR 1-3, n=847). Patients with positive FebriDx results were younger, more likely to be febrile and less likely to have raised neutrophil counts than FebriDx negative patients (supplementary table 3).

31.1% (41/132) of patients with a positive FebriDx had a positive SARS-CoV-2 RT-PCR, whilst only 4/826 (0.5%) with a negative FebriDx were diagnosed as having COVID-19. All 4 patients with falsenegative FebriDx results had normal chest radiographs. 2 patients tested negative for COVID-19 by SARS-CoV-2 RT-PCR but had positive FebriDx results and chest radiograph appearances typical for COVID-19. In the possible COVID-19 group, FebriDx results were available a median of 2.2 hours (IQR: 1.4 to 3.1, n=808) and RT-PCR results a median of 17.8 hours (IQR: 11.35 – 25.34, n=456) after arrival to the ED (figure 2). 88.0% of FebriDx results were available within 4 hours of arrival (n=808).

The triage algorithm correctly identified 126/136 patients with PCR-confirmed COVID-19 in the likely group (sensitivity 92.6%, 95%CI: 86.8 - 96.0) (table 3). The 10 patients who were SARS-CoV-2 RT-PCR positive but missed by the triage algorithm are described in supplementary table 4. 6/10 were classified as unlikely, and 4/10 were classified as possible COVID-19 and had a negative FebriDx. 2/10 were febrile on admission, none required supplemental oxygen, length of stay was short (median 2 days) and 8/8 had normal chest radiographs (2 did not have thoracic imaging done). Specificity of the algorithm was 86.4% (85.2 - 87.5), and negative predictive value was 99.7% (99.4 - 99.8).

#### Outcomes

94.9% (129/136) of patients with COVID-19 were appropriately managed in isolation rooms as a result of the triage algorithm (supplementary table 5). Of the 10 patients with PCR-confirmed COVID-19 not identified by the triage algorithm, only 7 were not managed in an isolation room. Had

all patients been isolated until SARS-CoV-2 RT-PCR result was available (ie without using any triage algorithm) 2,859 more isolation rooms would have been used. The FebriDx assay allowed 826 more patients to be managed in 'non-COVID' areas than if all patients triaged possible COVID-19 had required isolation (9.5 isolation rooms saved per day).

npare. g the admissi. groups (OR: 2.44, 95%) 11 (8.1%) patients with COVID-19 died compared to 150 (4.5%) without COVID-19 (p=0.042). Age and sex adjusted odds of death during the admission were higher for patients in the likely (OR: 3.42, 95% CI: 1.81 - 6.45) and possible groups (OR: 2.44, 95% CI: 1.73 - 3.44) than the unlikely COVID-19 group.

#### DISCUSSION

Our main findings are that a pragmatic triage algorithm using simple clinical parameters available within the ED and the FebriDx point-of-care test had good sensitivity (92.6%) and excellent NPV (99.7%) for COVID-19 diagnosed by RT-PCR. Inclusion of FebriDx improved the specificity of triage with minimal reductions in sensitivity, allowing a substantial reduction in the number of isolation rooms needed.

Although clinicians were able to identify patients likely and unlikely to have COVID-19 (45.7% and 0.3% of whom had confirmed COVID-19 respectively) based on clinical assessment, radiology and basic blood tests, their assessment was not sufficiently specific. Patients identified as 'possible' COVID-19 still had a 4% prevalence of COVID-19, and were a large enough group to overwhelm isolation room capacity. We demonstrate a simple, rapid test performed at the point-of-care can help further risk stratify this group. In real-life settings in a busy ED, a point-of-care test was able to inform isolation decisions within 4 hours of arrival compared to PCR results which were too slow to inform patient flow from ED, even when using 'rapid' PCR assays. Although formal cost-effectiveness analysis was not performed, each FebriDx test only costs about US\$18, and this may lead to cost savings.

The strengths of this study are its pragmatic design under routine clinical settings, and that we are able to account for over 95% of medical admissions, reducing risks of bias. There are, however, several limitations. A single SARS-CoV-2 RT-PCR is an imperfect reference standard, and does not account for RT-PCR negative COVID-19 patients. We used multiple RT-PCR platforms, which will have different PCR targets and performance. 10% of patients in the possible group did not get tested with FebriDx for unclear reasons, potentially introducing bias. The prevalence of COVID-19 was 4% in this cohort, and it is unclear what impact a higher prevalence of COVID-19 or other respiratory

pathogens such as influenza would have on these findings. The criteria for likely and possible COVID-19 groups changed subtly during the study period, although this is unlikely to significantly alter the outcomes.

These data build on previous studies of FebriDx showing good sensitivity, and utility as a 'rule-out' test for COVID-19.<sup>17–20</sup> We may have underestimated the sensitivity by not testing those patients deemed most likely to have COVID-19, although testing this group would have been unlikely to alter clinical decisions, even if FebriDx negative, given the high pre-test probability. The FebriDx test allowed patients with possible COVID-19 to be divided into two groups with similar characteristics and clinical features, but vastly different COVID-19 prevalence (0.5% in FebriDx negative, and 31.1% in FebriDx positive). However, about 10% of patients in this group were not eligible for FebriDx testing.

Only ten patients with COVID-19 were incorrectly triaged by the algorithm, four of whom were tested and 'missed' using FebriDx. These patients were younger, less symptomatic, did not have chest radiograph changes, and mostly likely had mild or asymptomatic COVID-19 infection. Given that MxA is an intracellular GTPase induced by type I and type III interferon responses, it is plausible that sensitivity would be lower in pauci- or asymptomatic infection.<sup>25</sup> Although the patients missed by the algorithm are potential sources of nosocomial transmission, asymptomatic disease is thought to be less transmissible.<sup>26</sup> We found no nosocomial cases related to these patients.

In conclusion, we demonstrate a simple triage system including the novel FebriDx point-of-care test had good sensitivity and negative predictive value for COVID-19 and utility for managing medical admissions from the ED.

#### Acknowledgements

We would like to acknowledge to all the clinical staff at Northwick Park Hospital who cared for the patients involved in this study. In particular, we give thanks to the point-of-care team for their outstanding work in establishing and running the new point-of-care testing service in the emergency department.

#### Funding statement

This research received no specific grant from any funding agency in the public, commercial or notfor-profit sectors.

#### **Author contributions**

HH, AGW, LJ, SF, JBL, JR, N Vaughan, N Vaid, GGR, and AKA made substantial contribution to the conception of the work. HH, AGW, LJ, and GD made substantial contribution to the design of the work. HH, GD, SN, KS, SP, MGD, and MT contributed to data acquisition. HH and AGW analysed the data. HH, AGW and LJ contributed to data interpretation. HH and AGW drafted the manuscript. All authors contributed to revising the manuscript critically for important intellectual content, approved the final manuscript and are accountable for all aspects of the work.

#### **Competing interests statement**

The authors have no competing interests to declare.

#### **Data availability statement**

Data are available upon reasonable request, subject to approval by the London North West University Healthcare NHS Trust Research and Governance Department and approval from relevant ethics and regulatory bodies.

## <u>References:</u>

- 1 Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med* 2020;8:687–95. doi:10.1016/S2213-2600(20)30193-4
- 2 Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London. *Clin Infect Dis* Published Online First: 8 July 2020. doi:10.1093/cid/ciaa905
- van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of
   SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.
   doi:10.1056/nejmc2004973
- Cevik M, Marcus JL, Buckee C, et al. Severe Acute Respiratory Syndrome Coronavirus
   2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy. *Clin Infect Dis* Published
   Online First: 23 September 2020. doi:10.1093/cid/ciaa1442
- 5 Rickman HM, Rampling T, Shaw K, et al. Nosocomial Transmission of Coronavirus Disease 2019: A Retrospective Study of 66 Hospital-acquired Cases in a London Teaching Hospital. *Clin Infect Dis* Published Online First: 20 June 2020. doi:10.1093/cid/ciaa816
- Verelst F, Kuylen E, Beutels P. Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020. *Eurosurveillance* 2020;25:1. doi:10.2807/1560-7917.ES.2020.25.13.2000323
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with
   2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA J Am Med
   Assoc 2020;323:1061–9. doi:10.1001/jama.2020.1585
- 8 Brendish NJ, Poole S, Naidu V V., et al. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. *Lancet Respir Med* 2020;8:1192– 200. doi:10.1016/S2213-2600(20)30454-9
- 9 NHS England. Pillar 1 NHS labs COVID-19 testing turnaround time data: 15 July 2020.
   2020. https://www.england.nhs.uk/coronavirus/publication/nhs-labs-covid-19testing-turnaround-time-data/
- 10 Gibani MM, Toumazou C, Sohbati M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. *The Lancet Microbe* 2020;1:e300–7. doi:10.1016/s2666-5247(20)30121-x
- 11 Collier DA, Assennato SM, Warne B, et al. Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. *Cell Reports Med* 2020;1. doi:10.1016/j.xcrm.2020.100062
- 12 Fink DL, Khan PY, Goldman N, et al. Development and internal validation of a diagnostic prediction model for COVID-19 at time of admission to hospital. *QJM An Int J Med* Published Online First: 9 November 2020. doi:10.1093/qjmed/hcaa305
- Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal. *BMJ* 2020;369:18. doi:10.1136/bmj.m1328
- 14 Engelmann I, Dubos F, Lobert PE, et al. Diagnosis of viral infections using myxovirus

1		
2		
3		resistance protein a (MxA). Pediatrics 2015;135:e985–93. doi:10.1542/peds.2014-
4		1946
5	15	Nakabayashi M, Adachi Y, Itazawa T, et al. MxA-based recognition of viral illness in
6 7	15	febrile children by a whole blood assay. <i>Pediatr Res</i> 2006;60:770–4.
8		•
9		doi:10.1203/01.pdr.0000246098.65888.5b
10	16	Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care
11		immunoassay to identify viral and/or bacterial immune response in patients with
12		acute febrile respiratory infection. Eur Clin Respir J 2015;2:28245.
13		doi:10.3402/ecrj.v2.28245
14	17	Thomas J, Pociute A, Kevalas R, et al. Blood biomarkers differentiating viral versus
15		bacterial pneumonia aetiology: A literature review. Ital. J. Pediatr. 2020;46:4.
16		doi:10.1186/s13052-020-0770-3
17	10	
18 19	18	Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host
20		response point-of-care test in patients hospitalised with suspected COVID-19. J Infect
20		2020;81:607–13. doi:10.1016/j.jinf.2020.06.051
22	19	Karim N, Ashraf MZ, Naeem M, et al. Utility of the FebriDx point-of-care test for rapid
23		triage and identification of possible coronavirus disease 2019 (COVID-19). Int J Clin
24		Pract Published Online First: 17 September 2020. doi:10.1111/ijcp.13702
25	20	National Institute for Health and Care Excellence. Overview   FebriDx for C-reactive
26	20	protein and myxovirus resistance protein A testing   Advice   NICE.
27		
28	24	https://www.nice.org.uk/advice/mib224/ (accessed 19 Dec 2020).
29	21	Ismail SA, Huntley C, Post N, et al. Horses for courses? Assessing the potential value of
30 31		a surrogate, point-of-care test for SARS-CoV-2 epidemic control. Influenza Other Respi
32		<i>Viruses</i> 2020;00:1– 4. doi:10.1111/irv.12796
33	22	Public Health England. COVID-19: infection prevention and control guidance.
34		https://www.publichealth.hscni.net/sites/default/files/2020-10/COVID-
35		19 Infection prevention and control guidance complete. 3.2
36		%2818 06 2020%29 0.pdf
37	23	Grant P, Turner M, Shin GY, et al. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by
38	25	
39		RT-PCR to increase capacity for national testing programmes during a pandemic.
40		<i>bioRxiv</i> [Preprint] Published Online First: 9 April 2020.
41		doi:10.1101/2020.04.06.028316
42 43	24	British Society of Thoracic Imaging. BSTI COVID-19 CXR Report Proforma.
43		https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUK
45		Ewj j4CurtrtAhUnQUEAHRTWA80QFjABegQIARAC&url=https%3A%2F%2Fwww.bsti.o
46		rg.uk%2Fmedia%2Fresources%2Ffiles%2FBSTI COVID CXR Proforma v.3-
47		1.pdf&usg=AOvVaw0vUxoui2fz68LEbrs6eTQm
48	25	Shirley M. FebriDx <sup>®</sup> : A Rapid Diagnostic Test for Differentiating Bacterial and Viral
49	25	
50		Aetiologies in Acute Respiratory Infections. <i>Mol Diagnosis Ther</i> 2019;23:803–9.
51		doi:10.1007/s40291-019-00433-x
52	26	Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load
53 54		dynamics, duration of viral shedding, and infectiousness: a systematic review and
54 55		meta-analysis. The Lancet Microbe 2020;0. doi:10.1016/s2666-5247(20)30172-5
56		
57		
58		
59		
60		

## <u>Tables</u>

COVID-19 triage category	Clinical Criteria	Diagnostics performed in ED	Bed Allocation from ED
	Recent Contact with a confirmed COVID-19 case OR Travel to High Risk country within the last 14 days	Routine RT- PCR	Isolation Room
Likely	Known COVID-19 illness confirmed prior to current attendance		COVID-19 cohort area or isolation room
	High Clinical Suspicion (eg. Oxygen Requirement, Bilateral infiltrates, Normal WCC/high CRP) OR Change in Normal sense of Smell or Taste	Urgent RT- PCR	Isolation Room
	Clinical or Radiological Pneumonia OR	FebriDx *	Isolation Room if FebriDx Positive
Possible	Fever / Persistent Cough / Shortness of Breath / Hypoxia / Diarrhoea / Confusion	Urgent RT- PCR	Non-COVID Area if FebriDx Negative
Unlikely	None of the Above	Routine RT- PCR	Non-COVID Area

Table 1. Clinical Criteria for determining triage groups, testing strategy and bed allocation from the Emergency Department prior to RT-PCR result. Clinical criteria for determining triage groups are shown as of 08/10/2020. Changes to these criteria over time are detailed in supplementary table 1. \* Patients were excluded from FebriDx testing if they had a prior history of COVID-19, were immunosuppressed, required intensive care or high dependency unit admission, or had had COVID-19 symptoms for > 10 days. RT-PCR=Reverse transcription polymerase chain reaction, ED=Emergency department

2	
2 3 4 5 6 7 8 9 10 11	
4	
6	
7	
8	
9 10	
11	
12	
13	
12 13 14 15 16 17	
16	
17	
18 19	
20	
21	
22	
23 24	
25	
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	
27	
20	
30	
31	
32 33	
34	
35	
36	
38	
39	
40	
41 42	
43	
44	
45	
46	

Unlikely	Possible	Likely	P-value
2033	1225	175	
69 (49, 82)	75 (60, 84)	62 (48, 74)	<0.001
1128 (55.5%, 53.3; 57.6)	846 (69.1%, 66.5; 71.6)	79 (45.1%, 37.8; 52.5)	<0.001
969 (47.7%, 45.5; 49.8)	603 (49.2%, 46.4; 52.0)	72 (41.1%, 33.9; 48.4)	0.045
1064 (52.3%, 50.2; 54.5)	622 (50.8%, 48.0; 53.6)	103 (58.9%, 51.6; 66.1)	
1 (0, 3)	4 (2, 6)	5 (3, 7)	0.017
18 (18, 20)	24 (20, 28)	24 (21, 32)	<0.001
61 (3.1%, 2.4; 3.9)	234 (19.5%, 17.3; 21.8)	38 (22.2%, 16.0; 28.5)	0.41
52 (2.7%, 2.0; 3.4)	245 (20.4%, 18.1; 22.7)	52 (30.4%, 23.5; 37.3)	0.003
172 (8.8%, 7.6; 10.1)	359 (30.0%, 27.4; 32.6)	73 (42.7%, 35.3; 50.1)	<0.001
1171 (81.0%, 79.0; 83.0)	537 (49.9%, 46.9; 52.9)	42 (29.8%, 22.2; 37.3)	<0.001
4 (0.3%, 0.0; 0.5)	25 (2.3%, 1.4; 3.2)	54 (38.3%, 30.3; 46.3)	<0.001
271 (18.7%, 16.7; 20.8)	514 (47.8%, 44.8; 50.8)	45 (31.9%, 24.2; 39.6)	<0.001
8 (23.5%, 9.3; 37.8)	9 (16.4%, 6.6; 26.1)	0 (0.0%, 0.0; 0.0)	0.25
0 (0.0%, 0.0; 0.0)	3 (5.4%, -0.5; 11.5)	3 (42.9%, 6.2; 79.5)	0.002
26 (76.5%, 62.2; 90.7)	43 (78.2%, 67.3; 89.1)	4 (57.1%, 20.5; 93.8)	0.22
5.7 (1.4, 26.9)	26.4 (7.05, 87.65)	53.7 (25.9, 122.7)	<0.001
545 (28.7%, 26.7; 30.7)	656 (55.8%, 52.9; 58.6)	134 (80.2%, 74.2; 86.3)	<0.001
373 (25.3%, 23.1; 27.5)	383 (43.9%, 40.6; 47.2)	70 (54.7%, 46.1; 63.3)	0.022
620 (32.0%, 29.9; 34.0)	598 (50.4%, 47.6; 53.3)	61 (36.1%, 28.9; 43.3)	<0.001
57 (2.8%, 2.1; 3.6)	89 (7.5%, 6.0; 9.0)	13 (7.8%, 3.7; 11.8)	0.89
	2033           69 (49, 82)           1128 (55.5%, 53.3; 57.6)           969 (47.7%, 45.5; 49.8)           1064 (52.3%, 50.2; 54.5)           1 (0, 3)           18 (18, 20)           61 (3.1%, 2.4; 3.9)           52 (2.7%, 2.0; 3.4)           172 (8.8%, 7.6; 10.1)           1171 (81.0%, 79.0; 83.0)           4 (0.3%, 0.0; 0.5)           271 (18.7%, 16.7; 20.8)           8 (23.5%, 9.3; 37.8)           0 (0.0%, 0.0; 0.0)           26 (76.5%, 62.2; 90.7)           5.7 (1.4, 26.9)           545 (28.7%, 26.7; 30.7)           373 (25.3%, 23.1; 27.5)           620 (32.0%, 29.9; 34.0)	2033         1225           69 (49, 82)         75 (60, 84)           1128 (55.5%, 53.3; 57.6)         846 (69.1%, 66.5; 71.6)           969 (47.7%, 45.5; 49.8)         603 (49.2%, 46.4; 52.0)           1064 (52.3%, 50.2; 54.5)         622 (50.8%, 48.0; 53.6)           1 (0, 3)         4 (2, 6)           18 (18, 20)         24 (20, 28)           61 (3.1%, 2.4; 3.9)         234 (19.5%, 17.3; 21.8)           52 (2.7%, 2.0; 3.4)         245 (20.4%, 18.1; 22.7)           172 (8.8%, 7.6; 10.1)         359 (30.0%, 27.4; 32.6)           1171 (81.0%, 79.0; 83.0)         537 (49.9%, 46.9; 52.9)           4 (0.3%, 0.0; 0.5)         25 (2.3%, 1.4; 3.2)           271 (18.7%, 16.7; 20.8)         514 (47.8%, 44.8; 50.8)           8 (23.5%, 9.3; 37.8)         9 (16.4%, 6.6; 26.1)           0 (0.0%, 0.0; 0.0)         3 (5.4%, -0.5; 11.5)           26 (76.5%, 62.2; 90.7)         43 (78.2%, 67.3; 89.1)           5.7 (1.4, 26.9)         26.4 (7.05, 87.65)           545 (28.7%, 26.7; 30.7)         656 (55.8%, 52.9; 58.6)           373 (25.3%, 23.1; 27.5)         383 (43.9%, 40.6; 47.2)           620 (32.0%, 29.9; 34.0)         598 (50.4%, 47.6; 53.3)           57 (2.8%, 2.1; 3.6)         89 (7.5%, 60.; 9.0)	2033         1225         175           69 (49, 82)         75 (60, 84)         62 (48, 74)           1128 (55.5%, 53.3; 57.6)         846 (69.1%, 66.5; 71.6)         79 (45.1%, 37.8; 52.5)           969 (47.7%, 45.5; 49.8)         603 (49.2%, 46.4; 52.0)         72 (41.1%, 33.9; 48.4)           1064 (52.3%, 50.2; 54.5)         622 (50.8%, 48.0; 53.6)         103 (58.9%, 51.6; 66.1)           1 (0, 3)         4 (2, 6)         5 (3, 7)           18 (18, 20)         24 (20, 28)         24 (21, 32)           61 (3.1%, 2.4; 3.9)         234 (19.5%, 17.3; 21.8)         38 (22.2%, 16.0; 28.5)           52 (2.7%, 2.0; 3.4)         245 (20.4%, 18.1; 22.7)         52 (30.4%, 23.5; 37.3)           172 (8.8%, 7.6; 10.1)         359 (30.0%, 27.4; 32.6)         73 (42.7%, 35.3; 50.1)           1171 (81.0%, 79.0; 83.0)         537 (49.9%, 46.9; 52.9)         42 (29.8%, 22.2; 37.3)           4 (0.3%, 0.0; 0.5)         25 (2.3%, 1.4; 3.2)         54 (38.3%, 30.3; 46.3)           271 (18.7%, 16.7; 20.8)         514 (47.8%, 44.8; 50.8)         45 (31.9%, 24.2; 39.6)           8 (23.5%, 9.3; 37.8)         9 (16.4%, 6.6; 26.1)         0 (0.0%, 0.0; 0.0)           0 (0.0%, 0.0; 0.0)         3 (54.%, -0.5; 11.5)         3 (42.9%, 6.2; 79.5)           26 (76.5%, 62.2; 90.7)         43 (78.2%, 67.3; 89.1)         4 (57.1%, 20.5; 93.8)

**BMJ** Open

Table 2: Baseline characteristics, vital signs, initial investigations, mortality and SARS-CoV-2 RT-PCR results for patients in the unlikely, possible and likely COVID-19 groups. For observations on arrival, 3.2 to 4.1% of data were missing. Data were missing for 5.5% of CRP results and 4.0% of haematology results, 22.4% of chest radiograph reports and 2.1% of discharge outcomes. 96 patients (2.8%) had a chest CT report available. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19. Chest CT reports were coded as: CVCT1= Classic/probable; CVCT2= Indeterminate; CVCT3= Non-COVID-19. Pair-wise comparisons were performed using chi-squared tests for proportions, t-tests for means and Wilcoxon rank sum for median. \*P-values are shown for the comparison between the possible and likely COVID-19 groups IQR=Inter-quartile range, CI=Confidence Interval, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, CT=Computerised Tomography

Tor beer review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Algorithm with FebriDx (n = 3433)		Algorithm without FebriDx (n=3433)		FebriDx only (n = 958)	
	n/N	% (95%Cl)	n/N	% (95%CI)	n/N	% (95%CI)
Sensitivity	126 / 136	92.6 (86.8 - 96.0)	130 / 136	95.6 (90.5 – 98.0)	41 / 45	91.1 (78.4 - 96.7)
Specificity	2849 / 3297	86.4 (85.2 - 87.5)	2027 / 3297	61.5 (59.8 – 63.1)	822 / 913	90.0 (87.9 - 91.8)
Negative Predictive Value	2849 / 2859	99.7 (99.4 - 99.8)	2027 / 2033	99.7 (99.3 – 99.9)	822 / 826	99.5 (98.7 - 99.8)
Positive Predictive Value	126 / 574	22.0 (18.8 - 25.5)	130 / 1400	9.3 (7.9 – 10.9)	41 / 132	31.1 (23.7 - 39.5)

Table 3 Measures of Diagnostic Performance for the Triage Algorithm (with and without FebriDx) and FebriDx assay alone for the detection of COVID-19, compared to the reference standard of SARS-COV-2 RT-PCR. Diagnostic performance measures are shown for three tests: the triage algorithm including the FebriDx test, the whole triage algorithm without FebriDx (ie patients in the likely or possible group classified as likely COVID-19, and for FebriDx alone. A cross-tabulaiton of positive and negative test results and reference standard are presented in supplementary table 2. CI = Confidence Interval

## Figure Legends:

## Figure 1: Patient flow through the study and the COVID-19 triage algorithm

Patients were included if they required admission to a medical ward from the ED between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 inclusive. Patients were excluded if they were under sixteen years of age, admitted under specialities other than medicine, or if their triage status or SARS-CoV-2 RT-PCR result was unknown. PCR = SARS-CoV-2 RT-PCR.

## Figure 2: Time from arrival to the availability of FebriDx and SARS-CoV-2 RT-PCR results

Kernel frequency density plot using the Epanechniko function; Time to FebriDx result was calculated as the time from arrival to the emergency department until the time the FebriDx result was recorded (blue plot), bandwidth=0.3; Time to RT-PCR result was calculated as the time from arrival to to the emergency department until the time the SARS-CoV-2 RT-PCR result was recorded (red plot), bandwidth=2.

or of the text of the second






Figure 1

494x494mm (37 x 37 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### <u>Use of the FebriDx point-of-care assay as part of a triage algorithm for medical admissions with</u> possible COVID-19

#### Supplementary Tables:

## Supplementary Table 1: Changes made to the inclusion criteria for the triage categories and the exclusion criteria for FebriDx testing during the study period.

	Date of Update to COVID-19 Triage Criteria					
	06/07/2020	09/09/2020	21/09/2020	08/10/2020		
		Confirmed COVID-19	during current illnes	S		
	(eg. Oxygen R	•	al Suspicion Il infiltrates, Normal '	WCC/high CRP)		
Likoly	Rece	ent Contact with a c	confirmed COVID-1	9 case		
Likely	Trave	l to High Risk count	ry within the last 1	4 days		
				Change in Normal sense of Smell or		
				Taste		
	Change in Normal sense of Smell or Taste					
	Clinical or Radiological Pneumonia					
Possible	Fever PLUS Persi	sistent Cough OR Fever OR Persistent Cough OR				
	Shortness of Brea	ath OR Hypoxia	Shortness of B	reath OR Hypoxia		
				Confusion OR		
				Diarrhoea		
Unlikely		None of t	the Above			
	Immunosuppressed					
Exclusion		Previous	COVID-19			
Criteria for FebriDx		R	equiring ITU/HDU/	NIV		
			COVID-19 Sym	nptoms >10 days		

Supplementary Table 1 footnotes:

The inclusion criteria for the triage categories and the exclusion criteria for FebriDx testing were adjusted during the course of this pragmatic study. WCC=white cell count, CRP= C-Reactive Protein, ITU=Intensive Therapy Unit, HDU=High Dependency Unit, NIV=Non-Invasive ventilation.

#### Supplementary Table 2:

		SA	RS-CoV-2 RT-PCR	
A		Positive	Negative	Total
Algorithm with FebriDx	Positive	126	448	574
(n=3433)	Negative	10	2849	2859
	Total	136	3297	3433

		SARS-CoV-2 RT-PCR		
В		Positive	Negative	Total
Algorithm without FebriDx	Positive	130	1270	1400
(n=3433)	Negative	6	2027	2033
( 2.00)	Total	136	3297	3433

		SARS-CoV-2 RT-PCR		
С		Positive	Negative	Total
	Positive	41	4	45
FebriDx only (n=958)	Negative	4	822	826
(11-556)	Total	45	913	958
			-	

Table 4 footnotes: Cross tabulation of results of the triage algorithm with FebriDx (A) and without FebriDx (B) as well as the results of FebriDx within the possible COVID-19 group receiving a FebriDx test (C) compared to a SARS-CoV-2 RT-PCR reference standard.

Respiratory Rate (breaths/min), median (IQR)

Required Supplemental Oxygen, n (%, 95%CI)

Chest Radiograph - Typical for COVID-19, n (%, 95%CI)

Temperature >37.5°C, n (%, 95%CI)

Chest Radiograph - Normal, n (%, 95%CI)

Chest Radiograph - Other, n (%, 95%CI)

Chest CT - Typical for COVID-19, n (%, 95%CI)

Lymphocyte Count <1.0x10^9/I, n (%, 95%CI)

SARS-CoV2 RNA Detectable on RT-PCR, n (%, 95%CI)

Neutrophil Count >7.5x10^9/l, n (%, 95%Cl)

Chest CT - Normal, n (%, 95%CI)

Chest CT - Other, n (%, 95%CI)

CRP (mg/L), median (IQR)

Mortality, n (%, 95%Cl)

CRP >20mg/L, n (%, 95%CI)

SpO2 <94%. n (%, 95%Cl)

15

16

17 18

19

20

21 22

23

24

25

26

27

28

29

30

31

32 33

34

35

36

37

43

44 45 46 **BMJ Open** 

Variable	FebriDx Negative	FebriDx Positive	FebriDx Not Done	FebriDx Positive vs Negative
N	826	132	267	
Age (years) median (IQR)	77 (61, 85)	69.5 (54.5, 81.5)	72 (60, 81)	<0.001
Age over 65 years, n (%, 95%CI)	586 (70.9, 67.8; 74.0)	80 (60.6, 52.0; 68.6)	180 (67.4, 61.5; 72.8)	0.017
Female Sex, n (%, 95%Cl)	399 (48.3, 44.9; 51.7)	63 (47.7, 39.3; 56.3)	141 (52.8, 46.8; 58.8)	0.90
Male Sex, n (%, 95%Cl)	427 (51.7, 48.3; 55.1)	69 (52.3, 43.7; 60.7)	126 (47.2, 41.2; 53.2)	
NEWS, median (IQR)	4 (2, 7)	4 (3, 6)	4 (2, 6)	0.62

24 (20, 28)

24 (18.6, 12.8; 26.3)

21 (16.3, 10.8; 23.7)

55 (42.6, 34.4; 51.4)

52 (43.3, 34.7; 52.4)

11 (9.2, 5.1; 15.8)

57 (47.5, 38.7; 56.5)

0 (0)

0 (0)

3 (100)

37.05 (17.1, 78.9)

87 (66.9, 58.4; 74.5)

46 (47.9, 38.1; 57.9)

50 (38.5, 30.5; 47.1)

6 (4.7, 2.1; 10.2)

41 (31.1, 23.7; 39.5)

24 (19, 28)

46 (17.9, 13.7; 23.1)

54 (21.0, 16.4; 26.5)

59 (23.0, 18.3; 28.6)

110 (49.1, 42.6; 55.7)

6 (2.7, 1.2; 5.9)

108 (48.2, 41.7; 54.8)

0 (0)

1 (16.7, 0.9; 81.4)

5 (83.3, 18.6; 99.1)

18.85 (4.9, 76.3)

126 (49.6, 43.5; 55.8)

74 (41.8, 34.7; 49.2)

126 (49.0, 42.9; 55.2)

18 (6.9, 4.4; 10.8)

5 (1.9, 0.8; 4.4)

0.74

0.67

0.23

0.005

< 0.001

< 0.001

0.97

0.40

0.71

0.34

0.012

0.019

0.455

0.002

0.19

< 0.001

24 (20, 28)

164 (20.2, 17.6; 23.1)

170 (20.9, 18.2; 23.8)

245 (30.2, 27.1; 33.4)

375 (51.2, 47.6; 54.9)

8 (1.1, 0.6; 2.2)

349 (47.7, 44.1; 51.3)

9 (19.6, 10.2; 34.1)

2 (4.4, 1.0; 16.5)

35 (76.1, 61.1; 86.5)

26.3 (6.5, 95.5)

443 (55.9, 52.5; 59.4)

263 (43.8, 39.9; 47.8)

422 (52.8, 49.3; 56.3)

65 (8.1, 6.4; 10.2)

4 (0.5, 0.3; 1.3)

Supplementary Table 2 footnotes: Missing data are summarised in the footnotes to table 2 in the main text. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19. Chest CT reports were coded as: CVCT0= Normal; CVCT1= Classic/probable; CVCT2= Indeterminate; CVCT3= Non-COVID-19. IQR=Inter-quartile range, CI=Confidence Interval, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, CT=Computerised Tomography

י ר	
2	
3 1	
4	
с С	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
34	
$\begin{array}{c} 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 9\\ 20\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 1\\ 32\\ 33\\ 34\\ 35\\ 37\\ 38\end{array}$	
36	
30	
20	
30 39	
39 40	
40 41	
41 42	
42 43	
44 45	
45	
46	

## Supplementary Table 4: Baseline characteristics of patients with positive SARS-CoV-2 RT-PCR results who were classified as triage negative by the algorithm

Case	1	2	3	4	5	6	7	8	9	10
Triage Status		Unlikely FebriDx Neg					Negative	gative		
Decade of Life*	5	7	3	5	7	6	6	3	7	5
Sex (F/M)	F	М	F	М	М	М	F	М	F	F
Presentation	Fever and epigastric pain	Hypoglycaemic collapse	Hyperkalaemia on clinic bloods	Herpes Zoster	Intentional Overdose	Unstable Angina	URTI symptoms	Diarrhoea	Fever and SOB	Headache and anosmia
Duration of Symptoms (days)	х	x	x	х	х	х	5	7	1	2
NEWS on Arrival	4	1	0	1	2	1	7	2	3	3
Respiratory Rate (breaths/min)	20	18	18	20	14	18	32	18	22	21
SpO2 (%)	97	96	100	96	93	98	94	100	96	100
Required Supplemental Oxygen (Y/N)	Ν	Ν	N	Ν	Ν	Ν	Ν	N	N	Ν
Temperature >37.5ºC, n (%, 95%Cl)	38.1	35.2	36.5	38	36.9	37	39.7	38.3	38.1	36.3
Chest Radiograph	CVCX0	CVCX0	ND	CVCX0	CVCX0	CVCX0	CVCX0	ND	CVCX0	CVCX0
CRP (mg/L)	9.5	2.6	2.6	4	0.7	57.1	16.4	0.9	5.1	68.5
Lymphocyte Count (x10^9/l)	0.5	1.4	2.2	1.1	3	0.7	2.2	1.2	0.5	0.7
Neutrophil Count (x10^9/l)	8.8	9.5	6.5	2.9	2.5	1.9	6.7	2.7	4.6	1.6
Isolated (Y / N)	Ν	Ν	Ν	Y	N	N	N	Y	Y	N
ICU Admission (Y / N)	Ν	N	Ν	N	N	N	N	N	N	N
Died (Y / N)	Ν	Ν	Ν	N	N	N	N	N	N	N
Length of stay (days)	2	1	1	1	7	2	4	2	4	1

Supplementary Table 3 footnotes: \*Age on arrival is presented in terms of Decade of Life (eg. 5 = age 40 to 49 years). Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, Y=Yes, N=No, ND=Not Done

Supplementary Table 5: Number of patients allocated to isolation rooms or COVID-19 cohorts in SARS-CoV-2 RT-PCR positive patients, and those requiring isolation following triage.

	SARS-CoV- 2 RT-PCR Positive (n=136)	Triage Positive (n=574)	Likely (n=175)	Possible, FebriDx Positive (n=132)	Possible, FebriDx Not Done (n=267)
'Non-COVID' Area	7	68	5	4	58
Side Room	112	477	152	122	203
COVID-19 Cohort Ward	17	29	18	6	6
% Isolated	94.9	88.2	97.1	97.0	78.3

Table 5 footnotes: Actual patient movement from the emergency department extracted from the hospital's bed management system.

management

## **STARD 2015**

### AIM

STARD stands for "Standards for Reporting Diagnostic accuracy studies". This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

#### EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test.** A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

#### DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select

items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <u>http://www.equator-network.org/reporting-guidelines/stard.</u>

Section & Topic	No	Item	Reported on pag #
TITLE OR			1
ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of	1
		accuracy	
		(such as sensitivity, specificity, predictive values, or AUC)	
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions	2
		(for specific guidance, see STARD for Abstracts)	
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of	4
		the index test	
	4	Study objectives and hypotheses	5
METHODS			
Study design	5	Whether data collection was planned before the index test and reference	5
		standard	
		were performed (prospective study) or after (retrospective study)	
Participants	6	Eligibility criteria	5, table 1 (page
	-	On what begin potentially aligible poticipants were identified	12) 5
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	5
	0		-
	8	Where and when potentially eligible participants were identified (setting,	5
	•	location and dates)	F
Tost mothods	9	Whether participants formed a consecutive, random or convenience series           Index test, in sufficient detail to allow replication	5
Test methods	10a		6
	10b	Reference standard, in sufficient detail to allow replication	6
	11	Rationale for choosing the reference standard (if alternatives exist)	NA
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	5
	126		
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	NA
	13a	Whether clinical information and reference standard results were available	6
	129	to the performers/readers of the index test	D
	13b	Whether clinical information and index test results were available	6
	130	to the assessors of the reference standard	0
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	7
החמוצטיט	14	How indeterminate index test or reference standard results were handled	7
	15	How missing data on the index test and reference standard results were handled	7
		Any analyses of variability in diagnostic accuracy, distinguishing pre-specified	
	17	from exploratory	NA
	18	Intended sample size and how it was determined	7
	το	ווונבוועבע שמווטוב שוב מווע ווטש זו שמש עבובוווווופע	1
RESULTS	10	Elow of participants, using a diagram	Eiguro 1 (page 17
Participants	19	Flow of participants, using a diagram	Figure 1 (page 17
	20	Baseline demographic and clinical characteristics of participants	Table 2 (page 18)

	21a	Distribution of severity of disease in those with the target condition	Table 2 (page 18
	21b	Distribution of alternative diagnoses in those without the target condition	NA
	22	Time interval and any clinical interventions between index test and reference standard	6
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 3 (page 20 and Supplementary Table 4
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Table 3 (page 2
	25	Any adverse events from performing the index test or the reference standard	NA
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	11
	27	Implications for practice, including the intended use and clinical role of the index test	12
OTHER INFORMATION		<u>V</u>	
	28	Registration number and name of registry	NA
	29	Where the full study protocol can be accessed	NA
	29	where the full study protocol can be accessed	INA
	30	Sources of funding and other support; role of funders	12
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	
		Sources of funding and other support; role of funders	

## STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	2
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			•
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of	5
Setting	5	recruitment, exposure, follow-up, and data collection	
Participants	6	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of	5 and
r	-	participants. Describe methods of follow-up	Table
			1
		( <i>b</i> ) For matched studies, give matching criteria and number of exposed and	
Variables	7	Unexposed	6
variables	/	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Ũ
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	7
measurement	0	assessment (measurement). Describe comparability of assessment methods if	
measurement		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	7
		describe which groupings were chosen and why	
Statistical methods	12	( <i>a</i> ) Describe all statistical methods, including those used to control for	7
		( <i>b</i> ) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		( <i>d</i> ) If applicable, explain how loss to follow-up was addressed	NA
		( <i>e</i> ) Describe any sensitivity analyses	7
Dogulta			
Results Participants	12*	(a) Report numbers of individuals at each stage of study—eg numbers	Figu
Participants	13*	potentially eligible, examined for eligibility, confirmed eligible, included in the	1
		study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	Figur
		(c) or reasons for non-participation at cach stage	1
		(c) Consider use of a flow diagram	Figur
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	Table
		and information on exposures and potential confounders	2

		(b) Indicate number of participants with missing data for each variable of interest	Tabi 2
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	9

to beet terien only

Main	16	(a)	Give unadjusted estimates and, if applicable, confounder-adjusted	ed estimates and	8
results			r precision (eg, 95% confidence interval). Make clear which con		
			usted for and why they were included		
		-	Report category boundaries when continuous variables were cate	egorized	Table 2
		( <i>c</i> )	If relevant, consider translating estimates of relative risk into abs	solute risk for a	
		mea	aningful time period		NA
	Other analyses	17	Report other analyses done—eg analyses of subgroups and	Supplementary	
			interactions, and sensitivity analyses	table 3	
	Discussion				_
	Key results	18	Summarise key results with reference to study objectives	Table 3	_
	Limitations	19	Discuss limitations of the study, taking into account sources	11	_
			of potential bias or imprecision. Discuss both direction and		
			magnitude of any potential bias		
	Interpretation	20	Give a cautious overall interpretation of results considering	12	_
			objectives, limitations, multiplicity of analyses, results from		
			similar studies, and other relevant evidence		
	Generalisability	21	Discuss the generalisability (external validity) of the study	12	_
			results		
	Other informati	ion			_
	Funding	22	Give the source of funding and the role of the funders for the	13	_
	-		present study and, if applicable, for the original study on		
			which the present article is based		
				÷	-

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

**BMJ** Open

# **BMJ Open**

# Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-049179.R1
Article Type:	Original research
Date Submitted by the Author:	18-Apr-2021
Complete List of Authors:	Houston, Hamish; London North West University Healthcare NHS Trust Deas, Gavin; Northwick Park Hospital Naik, Shivam; Imperial College London Shah, Kamal; Imperial College London Patel, Shiras; Imperial College London Greca Dottori, Maria; Imperial College London Tay, Michael; Imperial College London Filson, Sarah; London North West University Healthcare NHS Trust Biggin-Lamming, James; Northwick Park Hospital Ross, John; Northwick Park Hospital Vaughan, Natalie; Northwick Park Hospital Vaid, Nidhi; London North West University Healthcare NHS Trust Gopal Rao, Guduru; Northwick Park Hospital, Microbiology; Imperial College London, Amin, Amit K; Northwick Park Hospital Gupta-Wright, Ankur; University College London, Institute for Global Health John, Laurence; Northwick Park Hospital, Infectious Diseases
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	Diagnostics
Keywords:	COVID-19, Molecular diagnostics < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

## SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# **BMJ Open: Original Research Article**

# <u>Title:</u>

Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study

# <u>Authors:</u>

Hamish Houston<sup>a</sup>, Gavin Deas<sup>a</sup>, Shivam Naik<sup>b</sup>, Kamal Shah<sup>b</sup>, Shiras Patel<sup>b</sup>, Maria Greca Dottori<sup>b</sup>, Michael Tay<sup>b</sup>, Sarah Filson<sup>a</sup>, James Biggin-Lamming<sup>a</sup>, John Ross<sup>a</sup>, Natalie Vaughan<sup>a</sup>, Nidhi Vaid<sup>a</sup>, Guduru Gopal Rao<sup>a</sup>, Amit K Amin<sup>a,b</sup>, Ankur Gupta-Wright<sup>c,d,e\*</sup> Laurence John<sup>a</sup>\*

\*contributed equally

# Author Affiliations:

- a) Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, United Kingdom
- b) Imperial College School of Medicine, Imperial College London, London, United Kingdom
- c) Institute for Global Health, University College London, London, United Kingdom
- d) Ealing Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
- e) Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

# Corresponding Author:

Ankur Gupta-Wright

Institute for Global Health, University College London, Mortimer Market off Caper Street, London WC1E 6JB, United Kingdom

a.gupta-wright@ucl.ac.uk

+44(0)7764607560

Word Count: 2830 (abstract 277)

Keywords: FebriDx, MxA, triage algorithm, COVID-19, diagnostics.

Running Title: FebriDx triage for COVID-19

#### <u>ABSTRACT</u>

<u>Objective</u>: To evaluate a triage algorithm used to identify and isolate patients with suspected COVID-19 among medical patients needing admission to hospital using simple clinical criteria and the FebriDx assay.

Design: Retrospective observational cohort

Setting: Large acute NHS hospital in London, UK

<u>Participants:</u> All medical admissions from the emergency department between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 with a valid SARS-CoV-2 RT-PCR result.

Interventions: Medical admissions were triaged as likely, possible or unlikely COVID-19 based on clinical criteria. Patients triaged as possible COVID-19 underwent FebriDx lateral flow assay on capillary blood, and those positive for MxA were managed as likely COVID-19.

<u>Primary Outcome measures</u>: Diagnostic accuracy (sensitivity, specificity and predictive values) of the algorithm and the FebriDx assay compared to SARS-CoV-2 RT-PCR from nasopharyngeal swabs as the reference standard.

Results: 4.0% (136) of 3,443 medical admissions had RT-PCR confirmed COVID-19. Prevalence of COVID-19 was 46% (80/175) in those triaged as likely, 4.1% (50/1,225) in possible and 0.3% (6/2,033) in unlikely COVID-19. Compared to SARS-CoV-2 RT-PCR, clinical triage had sensitivity of 96% (95%CI: 91% - 98%) and specificity of 61.5% (95%CI: 59.8% - 63.1%), whilst the triage algorithm including FebriDx had sensitivity of 93% (95%CI: 87% - 96%) and specificity of 86.4% (95%CI: 85.2% - 87.5%). Whilst 2,033 patients were deemed not to require isolation using clinical criteria alone, the addition of FebriDx to clinical triage deisolated a further 826 patients from isolation, reducing the need for isolation rooms by 9.5 per day, 95%CI: 8.9 – 10.2. Ten patients missed by the algorithm had mild or asymptomatic COVID-19.

<u>Conclusions</u>: A triage algorithm including the FebriDx assay had good sensitivity and was useful to 'rule-out' COVID-19 among medical admissions to hospital.

#### STRENGTHS AND LIMITATIONS OF THIS STUDY

• Strengths

- This was a pragmatic study of a large cohort of consecutive medical admissions enabling a real-world evaluation of the utility of the FebriDx point-of-care assay for COVID-19 triage - a novel application.
- The analyses performed, including estimates of the number of isolation rooms saved and time-to-test result, can inform hospital management when assessing the effectiveness of the FebriDx point-of-care assay for COVID-19 triage in other settings.
- Limitations
  - A single SARS-CoV-2 RT-PCR is an imperfect reference standard for COVID-19 which may impact specificity, and multiple PCR assays were used each with their own performance characteristics.
  - The performance of the triage algorithm and the FebriDx assay may differ when used in other populations depending on the underlying prevalence of COVID-19 or other respiratory pathogens.

#### INTRODUCTION

The Coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, presents unprecedented challenges for infection prevention and control (IPC) within healthcare facilities worldwide.<sup>1</sup> Transmission may occur via respiratory droplet, fomite, or airborne routes (following aerosol-generating procedures).<sup>2-4</sup> Prolonged indoor contact increases transmission, and nosocomial transmission is common.<sup>5,6</sup> Respiratory isolation capacity (neutral or negative pressure side-rooms) is easily saturated within healthcare facilities.<sup>1</sup> Decisions to isolate patients in need of admission with suspected or possible COVID-19 must be rapid and accurate to maintain patient flow from emergency departments (EDs), yet minimise risk of nosocomial transmission.

As COVID-19 can present with non-specific symptoms, diagnostic confirmation is often sought by detection of SARS-CoV-2 ribonucleic acid (RNA) by reverse transcription-polymerase chain reaction (RT-PCR) from nasopharyngeal swab (NPS).<sup>7</sup> However, decisions about patient isolation from the ED are usually required before the results of RT-PCR assays are available.<sup>8,9</sup> Even near-patient, rapid RT-PCR platforms with assay run times of 1-2 hours can be quickly overwhelmed, especially during peaks of COVID-19 incidence.<sup>10,11</sup> Multivariable diagnostic risk models, including clinical criteria and thoracic imaging, are not sufficient, but may be useful as a triage test to ration expensive or scarce point-of care assays.<sup>12,13</sup>

FebriDx (Lumos diagnostics, Sarasota, Florida, US) is a lateral flow assay that detects two host response proteins, Myxovirus resistance protein A (MxA, positive if >40ng/mL) and C-reactive protein (CRP, positive if >20mg/L) in capillary blood samples. MxA is an interferon-induced antiviral host response protein that has been studied as a biomarker to differentiate bacterial and viral respiratory infections.<sup>14–17</sup> More recently FebriDx has demonstrated a sensitivity of 93% and specificity of 86% for detecting COVID-19 compared to RT-PCR in hospital inpatients including patients with clinically likely COVID-19 and those without symptoms of COVID-19.<sup>18</sup> FebriDx could be

#### **BMJ** Open

useful as an early triage tool to identify patients with COVID-19 and help guide isolation and IPC in patients needing admission to hospital.<sup>18–21</sup> We therefore developed and implemented a COVID-19 triage algorithm, supported by FebriDx, to inform patient flow from the ED whilst awaiting RT-PCR results. Here we describe the diagnostic performance of this algorithm compared to SARS-CoV-2 RT-PCR. We also describe the impact on isolation room demand and the time to FebriDx and RT-PCR results.

#### METHODS

#### Patient cohort

We utilised data prospectively entered into a COVID-19 triage database and retrospective extraction of clinical and bed allocation data from electronic patient records and hospital IT systems at Northwick Park Hospital, a large district general hospital serving a diverse population in North-West London. Patients were included if they required admission to a medical ward from the ED between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 inclusive and had a valid SARS-CoV-2 RT-PCR result on admission.

#### **Triage Algorithm**

On initial assessment in the ED, consecutive medical admissions were categorised by the attending clinician into three categories for their likelihood of COVID-19 (unlikely, possible and likely), using clinical criteria such as clinical history, observations and plain chest radiograph based on Public Health England guidance (Table 1 and Supplementary Table 1).<sup>22</sup> Patients discharged home or admitted under specialties other than medicine and those under sixteen years of age were not triaged using the algorithm and did not receive FebriDx testing, therefore their exclusion is unlikely to be a source of ascertainment bias. Patients with epidemiological risk factors for COVID-19 (eg. recent contact with a COVID-19 case or travel to a high-risk country) were triaged as likely COVID-19. We refer to this stage of the triage algorithm as 'clinical criteria'.

#### **BMJ** Open

We evaluated the impact of using FebriDx in a test-to-deisolate strategy amongst patients designated as possibly having COVID-19 after clinical criteria had been applied at initial assessment. Patients in the possible group underwent testing with FebriDx unless they declined or met an exclusion criterion. Patients were excluded from FebriDx testing if they were immunosuppressed or had had symptoms of COVID-19 for more than 10 days (in these situations a measurable Type I or Type III interferon response might not be present in infected individuals, as per manufacturer's guidance). Patients were also excluded if they had a previous diagnosis of COVID-19 (self-reported or confirmed) or required high dependency unit or intensive care unit (HDU/ICU) admission due to the greater infection control consequences of incorrect triage. All patients underwent NPS testing with SARS-COV-2 RT-PCR, with rapid RT-PCR assays being prioritised for patients in the likely group.

Only patients with confirmed COVID-19 on SARS-CoV-2 RT-PCR were admitted to a COVID-19 cohort area ('COVID ward'). Those triaged as likely, and those triaged as possible with a positive FebriDx or excluded from having a FebriDx test were designated 'Triage Positive' and admitted to an isolation room until PCR results were available. Patients assigned to the unlikely COVID-19 group and those with a negative FebriDx test were designated 'Triage Negative' and admitted to 'non-COVID wards' whilst awaiting SARS-CoV-2 RT-PCR results (Table 1 and Figure 1).

#### **Ethics Approval**

FebriDx testing was implemented as part of routine clinical care in response to data on assay performance for COVID-19 and an urgent clinical need.<sup>21</sup> The study was approved by the London North West University Hospitals Trust Research and Development Committee (SE20/069), and given this was a retrospective review using routinely collected clinical data, they deemed formal ethical approval was not required. Results are reported in compliance with STARD and STROBE guidelines

(see supplementary materials). The FebriDx tests were purchased independently from a UK distributer, and the manufacturer had no role in the study conception, design, data analysis or manuscript preparation.

#### Testing procedures and definitions

The FebriDx assay was performed as per the manufacturer's instructions at the point-of-care by trained ED health-care assistants. In brief, 5µL of capillary blood is placed on the sample window and reagents are released by pressing a button. The result is read after 10 minutes, with a positive result being the presence of a blue line in the control window and a red line in the MxA window (limit of detection 40ng/ml). The results from the CRP window were not used given all patients had laboratory CRP measurements. Staff performing FebriDx had access to clinical information but not SARS CoV-2 RT-PCR results at the time of FebriDx testing. Routine SARS CoV-2 RT-PCR was done on NPS using either the Panther Fusion SARS-CoV-2 (Hologic Inc, CA, USA), Abbott RealTime SARS-CoV-2 (Abbott Park, IL, USA) or an extraction-free SARS-CoV-2 RT-PCR assay developed by Health Services Laboratories (HSL), UK.<sup>23</sup> Rapid RT-PCR assays used were Xpert Xpress SARS-CoV-2 (Cepheid, CA, USA) or SAMBA II SARS-CoV-2 (Diagnostics for the Real World, CA, USA).

Patients were defined as having COVID-19 or not based on the first valid RT-PCR result up to 72 hours after admission. Patients without a valid RT-PCR result or triage status were excluded from the analysis. Vital signs, including National Early Warning Score (NEWS) were recorded on arrival to the ED. All biochemical, haematological and radiological data were from the first results within 48 hours of admission. Thoracic imaging (chest radiographs and CT) were reported and coded based upon guidelines on COVID-19 from the British Society of Thoracic Imaging (BSTI) at the time of reporting by radiologists.<sup>24</sup> Vital status is reported at the time of hospital discharge or data extraction (20<sup>th</sup> November 2020) for those who were still inpatients.

#### Data Analysis and Statistical Methods

We evaluated the real-world diagnostic performance (sensitivity, specificity, and positive and negative predictive values with 95% confidence intervals) of the triage algorithm (described above and in Figure 1) using both clinical criteria (described above and in Table 1) and the FebriDx assay in combination compared to a SARS-CoV-2 RT-PCR from a single NPS reference standard. We also evaluated each stage of the triage algorithm independently, estimating measures of diagnostic performance for triage using clinical criteria alone and the FebriDx assay in patients with possible COVID-19 compared to a SARS-CoV-2 RT-PCR reference standard. Patients with missing RT-PCR or those missing data on triaging were excluded from analysis. We also reported the time from arrival to FebriDx and RT-PCR results. We described the proportion of patients with COVID-19 who were correctly isolated, estimated the number of isolation beds made available by FebriDx testing, and described the patients with COVID-19 who were incorrectly triaged by the algorithm. Basic descriptive statistics were performed, with comparisons made using chi-squared tests for proportions, t-tests for means and Wilcoxon rank sum to compare non-normally distributed populations. Logistic regression was used to compare age and sex adjusted estimates of in-hospital death in each triage group, using complete cases only. Statistical analyses were performed using Stata version 14.0 (StataCorp, LLC, College Station TX). Based on an anticipated sensitivity of 93%, a sample size of 3335 would estimate the sensitivity of the triage algorithm ±5% with alpha 0.05 and prevalence of 3%.

#### **Patient and Public Involvement**

There was no patient involvement in the development of the research question, study design or conduct of the study.

#### RESULTS

#### **Baseline characteristics and COVID-19 diagnosis**

Between the 10<sup>th</sup> August and 4<sup>th</sup> November 2020, there were 9,645 emergency department visits resulting in further hospital care. Of these, 3,433 (35.6%) were adult medical patients admitted for further treatment, were triaged using the algorithm based on COVID-19 status and had a valid SARS-CoV-2 RT-PCR result (figure 1). 175 (5.1%) patients were triaged as likely COVID-19, 2,033 (59.2%) patients as unlikely COVID-19 and 1,225 (35.7%) patients were triaged into the possible COVID-19 category. Key patient characteristics are given in Table 2.

There were several differences between the three triage groups (Table 2). The likely COVID-19 group were younger, had higher NEWS scores on arrival and more frequently required supplemental oxygen compared to the unlikely group and the possible group (p<0.02 for all comparisons). As expected, more patients in the likely COVID-19 group had chest radiograph changes typical for COVID-19 than in the possible (p<0.001), and the unlikely COVID-19 group (p<0.001). The possible COVID-19 group were older than the other two groups and were more likely to have an elevated neutrophil count than the likely or possible groups.

Overall, 136/3,443 admissions (4.0%) were diagnosed with PCR-confirmed COVID-19. Prevalence of COVID-19 was 46% (80/175) in likely patients, and 4.1% (50/1,225) in the possible group. Of those triaged as unlikely COVID-19, only 6/2,033 (0.3%) were SARS-CoV-2 RT-PCR positive.

#### Performance of FebriDx and triage algorithm

The overall diagnostic performance of the clinical triage algorithm compared to the gold standard of SARS-CoV-2 RT-PCR is summarised in table 3. 958 (78.2%) patients in the possible group were tested using FebriDx (those excluded are detailed in figure 1). 13.8% (132/958) of FebriDx test results were positive for MxA, with 86.2% negative and no invalid results. The median duration of COVID-19

#### **BMJ** Open

symptoms in patients tested by FebriDx was 2 days (IQR 1-3, n=847). Patients with positive FebriDx results were younger, more likely to be febrile and less likely to have raised neutrophil counts than FebriDx negative patients (supplementary table 2).

31% (41/132) of patients with a positive FebriDx had a positive SARS-CoV-2 RT-PCR, whilst only 4/826 (0.5%) with a negative FebriDx were diagnosed as having COVID-19. All 4 patients with false-negative FebriDx results had normal chest radiographs. 2 patients tested negative for COVID-19 by SARS-CoV-2 RT-PCR but had positive FebriDx results and chest radiograph appearances typical for COVID-19. In the possible COVID-19 group, FebriDx results were available a median of 2.2 hours (IQR: 1.4 to 3.1, n=808) and RT-PCR results a median of 17.8 hours (IQR: 11.35 – 25.34, n=456) after arrival to the ED (figure 2). 88.0% of FebriDx results were available within 4 hours of arrival (n=808).

The triage algorithm correctly identified 126/136 patients with PCR-confirmed COVID-19 in the likely group (sensitivity 93%, 95%CI: 87 - 96) (table 3). The 10 patients who were SARS-CoV-2 RT-PCR positive but missed by the triage algorithm are described in supplementary table 3. 6/10 were classified as unlikely, and 4/10 were classified as possible COVID-19 and had a negative FebriDx. 2/10 were febrile on admission, none required supplemental oxygen, length of stay was short (median 2 days) and 8 had normal chest radiographs (2 did not have thoracic imaging done). Specificity of the algorithm was 86.4% (85.2 - 87.5), and negative predictive value was 99.7% (99.4 - 99.8).

#### Outcomes

95% (129/136) of patients with COVID-19 were appropriately managed in isolation rooms or COVID cohort wards as a result of the triage algorithm (supplementary table 4). Of the 10 patients with PCR-confirmed COVID-19 not identified by the triage algorithm, 7 were initially managed in a non-COVID ward. Had all patients been isolated until SARS-CoV-2 RT-PCR result was available (ie without using clinical criteria or FebriDx to de-isolate) 2,859 more isolation rooms would have been used.

#### **BMJ** Open

When using the triage algorithm, clinical criteria allowed 2,033 patients to be deisolated from isolation after being classified as unlikely COVID-19. The addition of FebriDx to clinical triage allowed 826 more patients to be managed in 'non-COVID' wards than if all patients triaged possible COVID-19 had required isolation (9.5 isolation rooms saved per day, 95%CI: 8.9 – 10.2).

.pared. .g. (Dr. 2.44, 95% Cr. 1 11 (8%) patients with COVID-19 died compared to 150 (4.5%) without COVID-19 (p=0.042). Age and sex adjusted odds of death during the admission were higher for patients in the likely (OR: 3.42, 95% CI: 1.81 - 6.45) and possible groups (OR: 2.44, 95% CI: 1.73 - 3.44) than the unlikely COVID-19 group.

#### DISCUSSION

Our main findings are that a pragmatic triage algorithm using simple clinical parameters available within the ED and the FebriDx point-of-care test had good sensitivity (93%) and excellent NPV (99.7%) for COVID-19 diagnosed by RT-PCR. Inclusion of FebriDx improved the specificity of triage with minimal reductions in sensitivity, allowing a substantial reduction in the number of isolation rooms needed.

Although clinicians were able to identify patients likely and unlikely to have COVID-19 (46% and 0.3% of whom had confirmed COVID-19 respectively) based on clinical assessment, radiology and basic blood tests, their assessment was not sufficiently specific. Patients identified as 'possible' COVID-19 still had a 4% prevalence of COVID-19, and were a large enough group to overwhelm isolation room capacity. We demonstrate a simple, rapid test performed at the point-of-care can help further risk stratify this group. In real-life settings in a busy ED, a point-of-care test was able to inform isolation decisions within 4 hours of arrival compared to PCR results which were too slow to inform patient flow from ED, even when using 'rapid' PCR assays. Although formal cost-effectiveness analysis was not performed, each FebriDx test only costs about US\$18, and this may lead to cost savings.

The strengths of this study are its pragmatic design under routine clinical settings, and that we are able to account for over 95% of medical admissions, reducing risks of bias. There are, however, several limitations. A single SARS-CoV-2 RT-PCR is an imperfect reference standard, and does not account for RT-PCR negative COVID-19 patients. We used multiple RT-PCR platforms, which will have different PCR targets and performance. 10% of patients in the possible group did not get tested with FebriDx for unclear reasons, which could be a source of bias unless these were unavoidable random losses in a busy ED department. The prevalence of COVID-19 was 4.0% in this cohort, and it is unclear what impact a higher prevalence of COVID-19 or other respiratory pathogens such as

influenza would have on these findings. The criteria for likely and possible COVID-19 groups changed subtly during the study period, although this is unlikely to significantly alter the outcomes.

These data build on previous studies of FebriDx showing good sensitivity, and utility as a 'rule-out' test for COVID-19.<sup>17–20</sup> The estimate of sensitivity of FebriDx for detecting COVID-19 in our cohort is lower than previously described, likely because our testing strategy differs in that it does not include patients deemed likely to have COVID-19 by clinical criteria. Testing this group would have been unlikely to alter clinical decisions, even if FebriDx had been negative, given the high pre-test probability. The FebriDx test allowed patients with possible COVID-19 to be divided into two groups with similar characteristics and clinical features, but vastly different COVID-19 prevalence (0.5% in FebriDx negative, and 31% in FebriDx positive). However, about 10% of patients in this group were not eligible for FebriDx testing, and had to be managed in isolation rooms as triage-positive patients (see Figure 1).

Only ten patients with COVID-19 were incorrectly triaged by the algorithm, four of whom were tested and 'missed' using FebriDx. These patients were younger, less symptomatic, did not have chest radiograph changes, and mostly likely had mild or asymptomatic COVID-19 infection. Given that MxA is an intracellular GTPase induced by type I and type III interferon responses, it is plausible that sensitivity would be lower in oligo- or asymptomatic infection.<sup>25</sup> Although the patients missed by the algorithm are potential sources of nosocomial transmission, asymptomatic disease is thought to be less transmissible.<sup>26</sup> We found no nosocomial cases related to these patients.

In conclusion, we demonstrate a simple triage system including the novel FebriDx point-of-care test had good sensitivity and negative predictive value for COVID-19 and utility for managing medical admissions from the ED.

1:

#### **Acknowledgements**

We would like to acknowledge to all the clinical staff at Northwick Park Hospital who cared for the patients involved in this study. In particular, we give thanks to the point-of-care team for their outstanding work in establishing and running the new point-of-care testing service in the emergency department.

#### **Funding statement**

This research received no specific grant from any funding agency in the public, commercial or notfor-profit sectors.

#### **Author contributions**

HH, AGW, LJ, SF, JBL, JR, N Vaughan, N Vaid, GGR, and AKA made substantial contribution to the conception of the work. HH, AGW, LJ, and GD made substantial contribution to the design of the work. HH, GD, SN, KS, SP, MGD, and MT contributed to data acquisition. HH and AGW analysed the data. HH, AGW and LJ contributed to data interpretation. HH and AGW drafted the manuscript. All authors contributed to revising the manuscript critically for important intellectual content, approved the final manuscript and are accountable for all aspects of the work.

#### **Competing interests statement**

The authors have no competing interests to declare.

#### **Data availability statement**

Data are available upon reasonable request, subject to approval by the London North West University Healthcare NHS Trust Research and Governance Department and approval from relevant ethics and regulatory bodies.

### **References:**

- Verelst F, Kuylen E, Beutels P. Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020. Euro Surveill. 2020 Apr;25(13):2000323. doi: 10.2807/1560-7917.ES.2020.25.13.2000323.
- 2 Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med* 2020;8:687–95. doi:10.1016/S2213-2600(20)30193-4
- 3 Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London. *Clin Infect Dis* Published Online First: 8 July 2020. doi:10.1093/cid/ciaa905
- 4 van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med* 2020;382:1564–7. doi:10.1056/nejmc2004973
- Cevik M, Marcus JL, Buckee C, et al. Severe Acute Respiratory Syndrome Coronavirus
   2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy. *Clin Infect Dis* Published
   Online First: 23 September 2020. doi:10.1093/cid/ciaa1442
- 6 Rickman HM, Rampling T, Shaw K, et al. Nosocomial Transmission of Coronavirus Disease 2019: A Retrospective Study of 66 Hospital-acquired Cases in a London Teaching Hospital. *Clin Infect Dis* Published Online First: 20 June 2020. doi:10.1093/cid/ciaa816
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with
   2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA J Am Med
   Assoc 2020;323:1061–9. doi:10.1001/jama.2020.1585
- 8 Brendish NJ, Poole S, Naidu V V., et al. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. *Lancet Respir Med* 2020;8:1192– 200. doi:10.1016/S2213-2600(20)30454-9
  - 9 NHS England. Pillar 1 NHS labs COVID-19 testing turnaround time data: 15 July 2020.
     2020. https://www.england.nhs.uk/coronavirus/publication/nhs-labs-covid-19testing-turnaround-time-data/
- 10 Gibani MM, Toumazou C, Sohbati M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. *The Lancet Microbe* 2020;1:e300–7. doi:10.1016/s2666-5247(20)30121-x
- 11 Collier DA, Assennato SM, Warne B, et al. Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. *Cell Reports Med* 2020;1. doi:10.1016/j.xcrm.2020.100062
- 12 Fink DL, Khan PY, Goldman N, et al. Development and internal validation of a diagnostic prediction model for COVID-19 at time of admission to hospital. *QJM An Int J Med* Published Online First: 9 November 2020. doi:10.1093/qjmed/hcaa305
- 13 Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal. *BMJ* 2020;369:18.

1		
2 3		de: 10.1120 /hm; m1220
4	14	doi:10.1136/bmj.m1328 Engelmann I, Dubos F, Lobert PE, et al. Diagnosis of viral infections using myxovirus
5 6 7	14	resistance protein a (MxA). <i>Pediatrics</i> 2015;135:e985–93. doi:10.1542/peds.2014- 1946
8	15	Nakabayashi M, Adachi Y, Itazawa T, et al. MxA-based recognition of viral illness in
9	10	febrile children by a whole blood assay. <i>Pediatr Res</i> 2006;60:770–4.
10 11		doi:10.1203/01.pdr.0000246098.65888.5b
12	16	Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care
13		immunoassay to identify viral and/or bacterial immune response in patients with
14 15		acute febrile respiratory infection. Eur Clin Respir J 2015;2:28245.
16		doi:10.3402/ecrj.v2.28245
17	17	Thomas J, Pociute A, Kevalas R, et al. Blood biomarkers differentiating viral versus
18		bacterial pneumonia aetiology: A literature review. Ital. J. Pediatr. 2020;46:4.
19 20		doi:10.1186/s13052-020-0770-3
20	18	Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host
22		response point-of-care test in patients hospitalised with suspected COVID-19. J Infect
23	40	2020;81:607–13. doi:10.1016/j.jinf.2020.06.051
24 25	19	Karim N, Ashraf MZ, Naeem M, et al. Utility of the FebriDx point-of-care test for rapid
26		triage and identification of possible coronavirus disease 2019 (COVID-19). Int J Clin
27	20	Pract Published Online First: 17 September 2020. doi:10.1111/ijcp.13702 National Institute for Health and Care Excellence. Overview   FebriDx for C-reactive
28 29	20	protein and myxovirus resistance protein A testing   Advice   NICE.
30		https://www.nice.org.uk/advice/mib224/ (accessed 19 Dec 2020).
31	21	Ismail SA, Huntley C, Post N, et al. Horses for courses? Assessing the potential value of
32		a surrogate, point-of-care test for SARS-CoV-2 epidemic control. <i>Influenza Other Respi</i>
33 34		<i>Viruses</i> 2020;00:1– 4. doi:10.1111/irv.12796
35	22	Public Health England. COVID-19: infection prevention and control guidance.
36		https://www.publichealth.hscni.net/sites/default/files/2020-10/COVID-
37 38		19_Infection_prevention_and_control_guidance_complete. 3.2
39		%2818_06_2020%29_0.pdf
40	23	Grant P, Turner M, Shin GY, et al. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by
41		RT-PCR to increase capacity for national testing programmes during a pandemic.
42 43		<i>bioRxiv</i> [Preprint] Published Online First: 9 April 2020.
44		doi:10.1101/2020.04.06.028316
45	24	British Society of Thoracic Imaging. BSTI COVID-19 CXR Report Proforma.
46 47		https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUK
47		Ewj_j4CurtrtAhUnQUEAHRTWA80QFjABegQIARAC&url=https%3A%2F%2Fwww.bsti.o
49		rg.uk%2Fmedia%2Fresources%2Ffiles%2FBSTI_COVID_CXR_Proforma_v.3-
50	25	1.pdf&usg=AOvVaw0vUxoui2fz68LEbrs6eTQm
51 52	25	Shirley M. FebriDx <sup>®</sup> : A Rapid Diagnostic Test for Differentiating Bacterial and Viral
53		Aetiologies in Acute Respiratory Infections. <i>Mol Diagnosis Ther</i> 2019;23:803–9. doi:10.1007/s40291-019-00433-x
54	26	Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load
55 56	20	dynamics, duration of viral shedding, and infectiousness: a systematic review and
50 57		meta-analysis. The Lancet Microbe 2020;0. doi:10.1016/s2666-5247(20)30172-5
58		
59 60		
60		

to peet terier only

# <u>Tables</u>

COVID- 19 triage category	Clinical Criteria	Diagnostics performed in ED	Bed Allocation from ED
	Recent Contact with a confirmed COVID-19 case OR Travel to High Risk country within the last 14 days	Routine RT-PCR	Isolation Room
Likely	Known COVID-19 illness confirmed within the last 14 days prior to current attendance		COVID-19 cohort ward or isolation room
	High Clinical Suspicion (eg. Oxygen Requirement, Bilateral infiltrates, Normal WCC/high CRP) OR Change in Normal sense of Smell or Taste	Urgent RT-PCR	Isolation Room
Possible	Clinical or Radiological Pneumonia OR Fever / Persistent Cough / Shortness of	FebriDx * &	FebriDx Positive (or not done) → Isolation Room
FUSSIBLE	Breath / Hypoxia / Diarrhoea / Confusion	م Urgent RT-PCR	FebriDx Negative → Non-COVID ward
Unlikely	None of the Above	Routine RT-PCR	Non-COVID ward

Table 1. Clinical Criteria for determining triage groups, testing strategy and bed allocation from the Emergency Department prior to RT-PCR result. Clinical criteria for determining triage groups are shown as of 08/10/2020. Changes to these criteria over time are detailed in supplementary table 1. \* Patients were excluded from FebriDx testing if they had a prior history of COVID-19, were immunosuppressed, required intensive care or high dependency unit admission, or had had COVID-19 symptoms for > 10 days. RT-PCR=Reverse transcription polymerase chain reaction, ED=Emergency department

Variable	Unlikely	Possible	Likely
Ν	2033	1225	175
Age (years) median (IQR)	69 (49, 82)	75 (60, 84)	62 (48, 74)
Age over 65 years, n (%, 95%CI)	1128 (55.5%, 53.3; 57.6)	846 (69.1%, 66.5; 71.6)	79 (45%, 38; 53)
Female Sex, n (%, 95%Cl)	969 (47.7%, 45.5; 49.8)	603 (49.2%, 46.4; 52.0)	72 (41%, 34; 48)
Male Sex, n (%, 95%Cl)	1064 (52.3%, 50.2; 54.5)	622 (50.8%, 48.0; 53.6)	103 (59%, 52; 66)
NEWS, median (IQR)	1 (0, 3)	4 (2, 6)	5 (3, 7)
Respiratory Rate (breaths/min), median (IQR)	18 (18, 20)	24 (20, 28)	24 (21, 32)
SpO2 <94%, n (%, 95%Cl)	61 (3.1%, 2.4; 3.9)	234 (19.5%, 17.3; 21.8)	38 (22%, 17; 29)
Required Supplemental Oxygen, n (%, 95%Cl)	52 (2.7%, 2.0; 3.4)	245 (20.4%, 18.1; 22.7)	52 (30%, 24; 38)
Temperature >37.5°C, n (%, 95%Cl)	172 (8.8%, 7.6; 10.1)	359 (30.0%, 27.4; 32.6)	73 (43%, 35; 50)
Chest Radiograph - Normal, n (%, 95%Cl)	1171 (81.0%, 79.0; 83.0)	537 (49.9%, 46.9; 52.9)	42 (30%, 22; 37)
Chest Radiograph - Typical for COVID-19, n (%, 95%CI)	4 (0.3%, 0.0; 0.5)	25 (2.3%, 1.4; 3.2)	54 (38%, 30; 46)
Chest Radiograph - Other, n (%, 95%CI)	271 (18.7%, 16.7; 20.8)	514 (47.8%, 44.8; 50.8)	45 (32%, 24; 40)
Chest CT - Normal, n (%, 95%CI)	8 (24%, 12; 41)	9 (16%, 9; 29)	0 (0%, 0; 0)
Chest CT - Typical for COVID-19, n (%, 95%CI)	0 (0%, 0; 0)	3 (5%, 2; 16)	3 (43%, 10; 83)
Chest CT - Other, n (%, 95%Cl)	26 (76%, 59; 88)	43 (78%, 65; 87)	4 (57%, 17; 90)
CRP (mg/L), median (IQR)	5.7 (1.4, 26.9)	26.4 (7.05, 87.65)	53.7 (25.9, 122.7)
CRP >20mg/L, n (%, 95%CI)	545 (28.7%, 26.7; 30.7)	656 (55.8%, 52.9; 58.6)	134 (80%, 74; 86)
Lymphocyte Count <1.0x10^9/l, n (%, 95%Cl)	373 (25.3%, 23.1; 27.5)	383 (43.9%, 40.6; 47.2)	70 (55%, 46; 63)
Neutrophil Count >7.5x10^9/l, n (%, 95%Cl)	620 (32.0%, 29.9; 34.0)	598 (50.4%, 47.6; 53.3)	61 (36%, 29; 43)
Crude In Hospital Mortality, n (%, 95%Cl)	57 (2.8%, 2.1; 3.6)	89 (7.5%, 6.0; 9.0)	13 (8%, 4; 12)
SARS-CoV-2 RNA Detectable on RT-PCR, n (%, 95%Cl)	6 (0.3%, 0.1; 0.5)	50 (4.1%, 3.0; 5.2)	80 (46%, 38; 53)

 Table 2: Baseline characteristics, vital signs, initial investigations, mortality and SARS-CoV-2 RT-PCR results for patients in the unlikely, possible and likely COVID-19 groups. For observations on arrival, 3.2 to 4.1% of data were missing. Data were missing for 5.5% of CRP results and 4.0% of haematology results, 22.4% of chest radiograph reports and 2.1% of vital status. 96 patients (2.8%) had a chest CT report available. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Typical; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19. Chest CT

 **BMJ** Open

reports were coded as: CVCT0= Normal; CVCT1= Typical; CVCT2= Indeterminate; CVCT3= Non-COVID-19. IQR=Inter-guartile range, CI=Confidence Interval, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, CT=Computerised Tomography

Le Indeterminal ations, CRP=C-Reactive s

·			SARS-CoV-2 RT-PCR			
A		Positive Negative To				
Likely or Possible COVID-19	130	1270	1400	PPV: 9.3% (95% CI: 7.9 – 10.9)		
3) Unlikely COVID-19	6	2027	2033	NPV: 99.7% (95% CI: 99.3 – 99.9)		
Total	136	3297	3433			
	Sensitivity 96% (95% Cl: 91 – 98)	Specificity 61.5% (95% CI: 59.8 – 63.1)				
	Possible COVID-19 Unlikely COVID-19	Possible COVID-19130Unlikely COVID-196Total136Sensitivity 96% (95% Cl: 91 – 98)	Possible COVID-191301270Unlikely COVID-1962027Total1363297SensitivitySpecificity96%61.5%	Possible COVID-19         130         1270         1400           Unlikely COVID-19         6         2027         2033           Total         136         3297         3433           Sensitivity         Specificity         3433           (95% CI: 91 – 98)         (95% CI: 59.8 – 63.1)         96%		

		SARS-0			
В	В		Negative	Total	
FebriDx alone in the possible	FebriDx Positive	41	91	132	PPV: 31% (95% CI: 24 – 39)
COVID-19 group with FebriDx done. (n=958)	FebriDx Negative	4	822	826	NPV: 99.5% (95% Cl: 98.7 – 99.8)
	Total	45	913	958	
		Sensitivity 91% (95% Cl: 78 – 97)	Specificity 90.0% (95% CI: 87.9 – 91.8)		

		SARS-			
С		Positive	Negative	Total	
	Triage	126	448	574	PPV:
Triage Algorithm	Positive	126	440	574	22% (95% Cl: 19 - 26)
using clinical criteria and	Triage Negative	10			NPV:
FebriDx (n=3433)			2849	2859	99.7%
					(95% CI: 99.4 - 99.8)
	Total	136	3297	3433	
		Sensitivity	Specificity		
		93%	86.4%		
		(95% CI: 87 - 96)	(95% CI: 85.2 - 87.5)		
	-			-	

Table 3 Cross tabulation of results of the triage algorithm with and without

FebriDx as well as the results of FebriDx within the possible COVID-19 group compared to a SARS-CoV-2 RT-PCR reference standard. Measures of Diagnostic Performance are presented for the triage algorithm for the detection of COVID-19: 3A) Using clinical criteria alone without FebriDx, where subjects are classified as positive or negative based on clinical criteria shown in Table 1. Subjects were 'positive' if they were assigned as likely or possible COVID-19 based on clinical criteria alone. 3B) Using the FebriDx assay alone within the possible COVID-19 group receiving a FebriDx test. Subjects are classed as FebriDx positive or negative based on the FebriDx test only. 3C) Using clinical criteria supported by the FebriDx assa. Subjects were classed as Triage positive or negative . thm Jussible C. Jittive Value, NI based on their flow through the algorithm as shown in figure 1. Patients were Triage positive if they were triaged as likely COVID-19 or possible COVID-19 without a negative FebriDx result. Patients were Triage Negative if they were triaged as unlikely COVID-19 or possible COVID-19 with a negative FebriDx result. PPV = Positive Predictive Value, NPV = Negative Predictive Value, CI = Confidence Interval

#### Figure Legends:

#### Figure 1: Patient flow through the study and the COVID-19 triage algorithm


Patients were included if they required admission to a medical ward from the ED between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 inclusive. Patients were excluded if they were under sixteen years of age, admitted under specialities other than medicine, or if their triage status or SARS-CoV-2 RT-PCR result was unknown. Counts at each stage of triage are shown in 2x2 tables on the right. These counts correspond with the 2x2 tables and measures of diagnostic performance shown in Table 3. PCR = SARS-CoV-2 RT-PCR.


#### Figure 2: Time from arrival to the availability of FebriDx and SARS-CoV-2 RT-PCR results


A e Eps gency del, JRT-PCR resu. Jime the SARS-Co Kernel frequency density plot using the Epanechniko function; Time to FebriDx result was calculated as the time from arrival to the emergency department until the time the FebriDx result was recorded (blue plot), bandwidth=0.3; Time to RT-PCR result was calculated as the time from arrival to to the emergency department until the time the SARS-CoV-2 RT-PCR result was recorded (red plot), bandwidth=2.

Page 25 of 36

BMJ Open







For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# <u>Use of the FebriDx point-of-care assay as part of a triage algorithm for medical admissions with</u> possible COVID-19

#### Supplementary Tables:

Supplementary Table 1: Changes made to the inclusion criteria for the triage categories and the exclusion criteria for FebriDx testing during the study period.

	Da	te of Update to CC	VID-19 Triage Crite	eria			
	06/07/2020	09/09/2020	21/09/2020	08/10/2020			
	Confirmed COVID-19 during current illness						
	High Clinical Suspicion (eg. Oxygen Requirement, Bilateral infiltrates, Normal WCC/high CRP)						
Likely	Rece	nt Contact with a c	confirmed COVID-19	Ə case			
LIKEIY	Travel	to High Risk count	ry within the last 14	4 days			
				Change in Normal sense of Smell or			
				Taste			
	Change in Normal sense of Smell or Taste						
	Clinical or Radiological Pneumonia						
Possible		sistent Cough OR Fever OR Persistent Cough OR					
	Shortness of Brea	ath OR Hypoxia	Shortness of Breath OR Hypoxia				
				Confusion OR Diarrhoea			
Unlikely	None of the Above						
	Immunosuppressed						
Exclusion		Previous	COVID-19				
Criteria for FebriDx		R	equiring ITU/HDU/	NIV			
CONDA			COVID-19 Sym	ptoms >10 days			

Supplementary Table 1 footnotes:

The inclusion criteria for the triage categories and the exclusion criteria for FebriDx testing were adjusted during the course of this pragmatic study. WCC=white cell count, CRP= C-Reactive Protein, ITU=Intensive Therapy Unit, HDU=High Dependency Unit, NIV=Non-Invasive ventilation.

2
3
4
5
6
7
/
8
9
10
11
12
13
14
15
16
10
17
<ul> <li>8</li> <li>9</li> <li>10</li> <li>11</li> <li>12</li> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> <li>26</li> <li>27</li> <li>28</li> <li>29</li> <li>30</li> </ul>
19
20
21
22
23
24
27
25
20
27
28
29
30
31
32 33
34
34 35
26
20
36 37 38 39
38
40
41
42
43
44
45
45

1

# Supplementary Table 2: Baseline characteristics, vital signs, initial investigations, mortality and SARS-CoV-2 RT-PCR results for patients in the possible COVID-19 group by FebriDx test result

Variable	FebriDx Negative	FebriDx Positive	FebriDx Not Done
Ν	826	132	267
Age (years) median (IQR)	77 (61, 85)	69.5 (54.5, 81.5)	72 (60, 81)
Age over 65 years, n (%, 95%Cl)	586 (70.9, 67.8; 74.0)	80 (61, 52; 69)	180 (67, 62; 73)
Female Sex, n (%, 95%Cl)	399 (48.3, 44.9; 51.7)	63 (48, 39; 56)	141 (53, 47; 59)
Male Sex, n (%, 95%Cl)	427 (51.7, 48.3; 55.1)	69 (52, 44; 61)	126 (47, 41; 53)
NEWS, median (IQR)	4 (2, 7)	4 (3, 6)	4 (2, 6)
Respiratory Rate (breaths/min), median (IQR)	24 (20, 28)	24 (20, 28)	24 (19, 28)
SpO2 <94%, n (%, 95%Cl)	164 (20.2, 17.6; 23.1)	24 (19, 13; 26)	46 (18, 14; 23)
Required Supplemental Oxygen, n (%, 95%Cl)	170 (20.9, 18.2; 23.8)	21 (16, 11; 24)	54 (21, 16; 26)
Temperature >37.5ºC, n (%, 95%Cl)	245 (30.2, 27.1; 33.4)	55 (43, 34; 51)	59 (23, 18; 29)
Chest Radiograph - Normal, n (%, 95%Cl)	375 (51.2, 47.6; 54.9)	52 (43, 35; 52)	110 (49, 43; 56)
Chest Radiograph - Typical for COVID-19, n (%, 95%CI)	8 (1.1, 0.6; 2.2)	11 (9, 5; 16)	6 (3, 1; 6)
Chest Radiograph - Other, n (%, 95%Cl)	349 (47.7, 44.1; 51.3)	57 (48, 39; 57)	108 (48, 42; 55)
Chest CT - Normal, n (%, 95%CI)	9 (20, 10; 34)	0 (0)	0 (0)
Chest CT - Typical for COVID-19, n (%, 95%CI)	2 (4, 1; 17)	0 (0)	1 (17, 1; 81)
Chest CT - Other, n (%, 95%Cl)	35 (76, 61; 87)	3 (100)	5 (83, 19; 99)
CRP (mg/L), median (IQR)	26 (7, 96)	37.05 (17.1, 78.9)	18.85 (4.9, 76.3)
CRP >20mg/L, n (%, 95%Cl)	443 (55.9, 52.5; 59.4)	87 (67, 58; 75)	126 (50, 43; 56)
Lymphocyte Count <1.0x10^9/l, n (%, 95%CI)	263 (43.8, 39.9; 47.8)	46 (48, 38; 58)	74 (42, 35; 49)
Neutrophil Count >7.5x10^9/l, n (%, 95%Cl)	422 (52.8, 49.3; 56.3)	50 (38, 30; 47)	126 (49, 43; 55)
Mortality, n (%, 95%Cl)	65 (8.1, 6.4; 10.2)	6 (5, 2; 10)	18 (7, 4; 11)
SARS-CoV2 RNA Detectable on RT-PCR, n (%, 95%Cl)	4 (0.5, 0.3; 1.3)	41 (31, 24; 40)	5 (2, 1; 4)

Supplementary Table 2 footnotes: Missing data are summarised in the footnotes to table 2 in the main text. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19. Chest CT reports were coded as: CVCT0= Normal; CVCT1= Classic/probable; CVCT2= Indeterminate; CVCT3= Non-COVID-19. IQR=Inter-quartile range, CI=Confidence Interval, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, CT=Computerised Tomography

 BMJ Open

Case	1	2	3	4	5	6	7	8	9	1
Triage Status		<u> </u>	Unlikely				Possible, FebriDx Negative			
Decade of Life*	5	7	3	5	7	6	6	3	7	5
Sex (F/M)	F	М	F	М	М	М	F	М	F	F
Presentation	Fever and epigastric pain	Hypoglycaemic collapse	Hyperkalaemia on clinic bloods	Herpes Zoster	Intentional Overdose	Unstable Angina	URTI symptoms	Diarrhoea	Fever and SOB	Head an anos
Duration of Symptoms (days)	х	x	х	x	x	x	5	7	1	2
NEWS on Arrival	4	1	0	1	2	1	7	2	3	3
Respiratory Rate (breaths/min)	20	18	18	20	14	18	32	18	22	2
SpO2 (%)	97	96	100	96	93	98	94	100	96	10
Required Supplemental Oxygen (Y/N)	Ν	N	N	Ν	Ν	N	Ν	N	N	Ν
Temperature ⁰C	38.1	35.2	36.5	38	36.9	37	39.7	38.3	38.1	36
Chest Radiograph	CVCX0	CVCX0	ND	CVCX0	CVCX0	CVCX0	CVCX0	ND	CVCX0	CVC
CRP (mg/L)	9.5	2.6	2.6	4	0.7	57.1	16.4	0.9	5.1	68
Lymphocyte Count (x10^9/l)	0.5	1.4	2.2	1.1	3	0.7	2.2	1.2	0.5	0.
Neutrophil Count (x10^9/l)	8.8	9.5	6.5	2.9	2.5	1.9	6.7	2.7	4.6	1.
Isolated (Y / N)	Ν	N	Ν	Y	N	N	N	Y	Y	Ν
ICU Admission (Y / N)	Ν	N	Ν	Ν	N	N	N	N	Ν	Ν
Died (Y / N)	Ν	N	Ν	Ν	N	N	N	N	Ν	Ν
Length of stay (days)	2	1	1	1	7	2	4	2	4	1

Supplementary Table 3 footnotes: \*Age on arrival is presented in terms of Decade of Life (eg. 5 = age 40 to 49 years). Duration of symptoms was recorded only for patients with a clinical syndrome compatible with COVID-19 tested by FebriDx. Observations presented are those measured on arrival to the Emergency Department. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic;

CVCX2 = Indeterminate; CVCX3 = Non-COVID-19, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, Y=Yes, N=No, ND=Not Done

For peer review only

Supplementary Table 4: Actual bed allocation to isolation rooms or COVID-19 cohorts in SARS-CoV-2 RT-PCR positive patients, and those requiring isolation following triage.

	SARS-CoV- 2 RT-PCR Positive (n=136)	Triage Positive (n=574)	Likely (n=175)	Possible, FebriDx Positive (n=132)	Possible, FebriDx Not Done (n=267)
'Non-COVID' Ward	7	68	5	4	58
Isolation Room	112	477	152	122	203
COVID-19 Cohort Ward	17	29	18	6	6
% Isolated	95	88.2	97	97	78

Table 4 footnotes: Actual patient movement from the emergency department extracted from the hospital's bed management system.

management -,

### **STARD 2015**

#### AIM

STARD stands for "Standards for Reporting Diagnostic accuracy studies". This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

#### EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test.** A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

#### DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select

items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <u>http://www.equator-network.org/reporting-guidelines/stard.</u>

Section & Topic	No	Item	Reported on page #	
TITLE OR			1	
ABSTRACT				
	1	Identification as a study of diagnostic accuracy using at least one measure of	1	
		accuracy		
		(such as sensitivity, specificity, predictive values, or AUC)		
ABSTRACT				
	2	Structured summary of study design, methods, results, and conclusions	2	
		(for specific guidance, see STARD for Abstracts)		
INTRODUCTION				
	3	Scientific and clinical background, including the intended use and clinical role of	4	
		the index test		
	4	Study objectives and hypotheses	5	
METHODS				
Study design	5	Whether data collection was planned before the index test and reference	5	
		standard		
		were performed (prospective study) or after (retrospective study)		
Participants	6	Eligibility criteria	5, table 1 (page	
			12)	
	7	On what basis potentially eligible participants were identified	5	
		(such as symptoms, results from previous tests, inclusion in registry)		
	8	Where and when potentially eligible participants were identified (setting,	5	
		location and dates)		
	9	Whether participants formed a consecutive, random or convenience series	5	
Test methods	10a	Index test, in sufficient detail to allow replication	6	
	10b	Reference standard, in sufficient detail to allow replication	6	
	11	Rationale for choosing the reference standard (if alternatives exist)	NA	
	12a	Definition of and rationale for test positivity cut-offs or result categories	5	
		of the index test, distinguishing pre-specified from exploratory		
	12b	Definition of and rationale for test positivity cut-offs or result categories	NA	
		of the reference standard, distinguishing pre-specified from exploratory		
	13a	Whether clinical information and reference standard results were available	6	
		to the performers/readers of the index test		
	13b	Whether clinical information and index test results were available	6	
		to the assessors of the reference standard		
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	7	
	15	How indeterminate index test or reference standard results were handled	7	
	16	How missing data on the index test and reference standard were handled	7	
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified	NA	
		from exploratory		
	18	Intended sample size and how it was determined	7	
RESULTS				
Participants	19	Flow of participants, using a diagram	Figure 1 (page 17	
	20	Baseline demographic and clinical characteristics of participants	Table 2 (page 18)	

	21a	Distribution of severity of disease in those with the target condition	Table 2 (page 18)
	21b	Distribution of alternative diagnoses in those without the target condition	NA
	22	Time interval and any clinical interventions between index test and reference standard	6
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 3 (page 20 and Supplementary Table 4
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Table 3 (page 20
	25	Any adverse events from performing the index test or the reference standard	NA
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	11
	27	Implications for practice, including the intended use and clinical role of the index test	12
OTHER INFORMATION			
	28	Registration number and name of registry	NA
	29	Where the full study protocol can be accessed	NA
	30	Sources of funding and other support; role of funders	12

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	2
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	4
		reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of	5
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	5 and
		participants. Describe methods of follow-up	Table
		(b) For matched studies, give matching criteria and number of exposed and	-
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	6
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	7
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	7
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	7
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA
		( <i>e</i> ) Describe any sensitivity analyses	7
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	Figu
		potentially eligible, examined for eligibility, confirmed eligible, included in the	1
		study, completing follow-up, and analysed	1
		(b) Give reasons for non-participation at each stage	Figur
		(c) Consider use of a flow diagram	1
		(c) Consider use of a now diagram	Figu
	4 4.0		1 Table
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	2

		(b) Indicate number of participants with missing data for each variable of interest	Tabl 2
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	9

to beet teries only

Main	16	( <i>a</i> )	Give unadjusted estimates and, if applicable, confounder-adjuste	ed estimates and	8
results		thei	r precision (eg, 95% confidence interval). Make clear which con	founders were	
		adjı	usted for and why they were included		
		( <i>b</i> )	Report category boundaries when continuous variables were cate	egorized	Table 2
		(c)	If relevant, consider translating estimates of relative risk into abs	olute risk for a	
		mea	aningful time period		NA
	Other analyses	17	Report other analyses done-eg analyses of subgroups and	Supplementary	
			interactions, and sensitivity analyses	table 3	
	Discussion				_
	Key results	18	Summarise key results with reference to study objectives	Table 3	_
	Limitations	19	Discuss limitations of the study, taking into account sources	11	-
			of potential bias or imprecision. Discuss both direction and		
			magnitude of any potential bias		
	Interpretation	20	Give a cautious overall interpretation of results considering	12	-
			objectives, limitations, multiplicity of analyses, results from		
			similar studies, and other relevant evidence		
	Generalisability	21	Discuss the generalisability (external validity) of the study	12	-
			results		
	Other informati	on			-
	Funding	22	Give the source of funding and the role of the funders for the	13	_
			present study and, if applicable, for the original study on		
			which the present article is based		

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

**BMJ** Open

# **BMJ Open**

# Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-049179.R2
Article Type:	Original research
Date Submitted by the Author:	07-Jun-2021
Complete List of Authors:	Houston, Hamish; London North West University Healthcare NHS Trust Deas, Gavin; Northwick Park Hospital Naik, Shivam; Imperial College London Shah, Kamal; Imperial College London Patel, Shiras; Imperial College London Greca Dottori, Maria; Imperial College London Tay, Michael; Imperial College London Filson, Sarah; London North West University Healthcare NHS Trust Biggin-Lamming, James; Northwick Park Hospital Ross, John; Northwick Park Hospital Vaughan, Natalie; Northwick Park Hospital Vaid, Nidhi; London North West University Healthcare NHS Trust Gopal Rao, Guduru; Northwick Park Hospital, Microbiology; Imperial College London, Amin, Amit K; Northwick Park Hospital Gupta-Wright, Ankur; University College London, Institute for Global Health John, Laurence; Northwick Park Hospital, Infectious Diseases
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	Diagnostics
Keywords:	COVID-19, Molecular diagnostics < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# **BMJ Open: Original Research Article**

#### **Title**:

 Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study

# 6 <u>Authors:</u>

7 Hamish Houston<sup>a</sup>, Gavin Deas<sup>a</sup>, Shivam Naik<sup>b</sup>, Kamal Shah<sup>b</sup>, Shiras Patel<sup>b</sup>, Maria

- 8 Greca Dottori<sup>b</sup>, Michael Tay<sup>b</sup>, Sarah Filson<sup>a</sup>, James Biggin-Lamming<sup>a</sup>, John Ross<sup>a</sup>, Natalie
- 9 Vaughan<sup>a</sup>, Nidhi Vaid<sup>a</sup>, Guduru Gopal Rao<sup>a</sup>, Amit K Amin<sup>a,b</sup>, Ankur Gupta-Wright<sup>c,d,e\*</sup>
- 10 Laurence John<sup>a\*</sup>

# \*contributed equally

# 14 <u>Author Affiliations:</u>

- a) Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, United Kingdom
  - b) Imperial College School of Medicine, Imperial College London, London, United Kingdom
- c) Institute for Global Health, University College London, London, United Kingdom
- d) Ealing Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
  - e) Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

#### 

## **Corresponding Author:**

- <sup>36</sup> <sub>37</sub> 26 Ankur Gupta-Wright
- 27 Institute for Global Health, University College London, Mortimer Market off Caper Street,
- 39 28 London WC1E 6JB, United Kingdom
- 40 29 <u>a.gupta-wright@ucl.ac.uk</u> 41 20 +44(0)77C4C07FC0
  - 30 +44(0)7764607560
    - 32 Word Count: 3067 (abstract 290)
    - 34 <u>Keywords:</u> FebriDx, MxA, triage algorithm, COVID-19, diagnostics.
- 48 33 49 36 <u>Running Title:</u> FebriDx triage for COVID-19

1		
2 3 4	1	ABSTRACT
5 6	2	Objective: To evaluate a triage algorithm used to identify and isolate patients with suspected COVID-
7 8	3	19 among medical patients needing admission to hospital using simple clinical criteria and the
9 10 11	4	FebriDx assay.
12 13	5	Design: Retrospective observational cohort
14 15	6	Setting: Large acute NHS hospital in London, UK
16 17 18	7	Participants: All medical admissions from the emergency department between 10 <sup>th</sup> August 2020 and
19 20	8	4 <sup>th</sup> November 2020 with a valid SARS-CoV-2 RT-PCR result.
21 22	9	Interventions: Medical admissions were triaged as likely, possible or unlikely COVID-19 based on
23 24	10	clinical criteria. Patients triaged as possible COVID-19 underwent FebriDx lateral flow assay on
25 26 27	11	capillary blood, and those positive for myxovirus resistance protein A (a host response protein) were
27 28 29	12	managed as likely COVID-19.
30 31	13	Primary Outcome measures: Diagnostic accuracy (sensitivity, specificity and predictive values) of the
32 33	14	algorithm and the FebriDx assay using SARS-CoV-2 RT-PCR from nasopharyngeal swabs as the
34 35 26	15	reference standard.
36 37 38	16	Results: 4.0% (136) of 3,443 medical admissions had RT-PCR confirmed COVID-19. Prevalence of
39 40	17	COVID-19 was 46% (80/175) in those triaged as likely, 4.1% (50/1,225) in possible and 0.3% (6/2,033)
41 42	18	in unlikely COVID-19. Using a SARS-CoV-2 RT-PCR reference standard, clinical triage had sensitivity of
43 44	19	96% (95%CI: 91% - 98%) and specificity of 61.5% (95%CI: 59.8% - 63.1%), whilst the triage algorithm
45 46 47	20	including FebriDx had sensitivity of 93% (95%CI: 87% - 96%) and specificity of 86.4% (95%CI: 85.2% -
48 49	21	87.5%). Whilst 2,033 patients were deemed not to require isolation using clinical criteria alone, the
50 51	22	addition of FebriDx to clinical triage allowed a further 826 patients to be released from isolation,
52 53	23	reducing the need for isolation rooms by 9.5 per day, 95%CI: 8.9 – 10.2. Ten patients missed by the
54 55 56	24	algorithm had mild or asymptomatic COVID-19.
57 58	25	Conclusions: A triage algorithm including the FebriDx assay had good sensitivity and was useful to
59 60	26	'rule-out' COVID-19 among medical admissions to hospital.

This was a pragmatic study of a large cohort of consecutive medical admissions

enabling a real-world evaluation of the utility of the FebriDx point-of-care assay for

The analyses performed, including estimates of the number of isolation rooms saved

and time-to-test result, can inform hospital management when assessing the

effectiveness of the FebriDx point-of-care assay for COVID-19 triage in other

A single SARS-CoV-2 RT-PCR is an imperfect reference standard for COVID-19 which

may impact specificity, and multiple PCR assays were used each with their own

The performance of the triage algorithm and the FebriDx assay may differ when

used in other populations depending on the underlying prevalence of COVID-19 or

The clinical triage criteria were adjusted during the study period to reflect evolving

national guidance which may limit the reproducibility of our results.

1 2	
- 3 4	1
5 6	2
7 8	3
9 10 11	4
11 12 13	5
14 15	6
16 17	7
18 19	8
20 21	9
22 23 24	10
24 25 26	11
27 28	12
29 30	13
31 32	14
33 34 35	15
36 37	16
38 39	17
40 41	18
42 43	10
44 45	20
46 47 48	20
49 50	
51 52	22
53 54	23
55 56	
57 58	
59 60	

#### 1 STRENGTHS AND LIMITATIONS OF THIS STUDY

settings.

COVID-19 triage - a novel application.

performance characteristics.

other respiratory pathogens.

Strengths

0

0

Limitations

0

0

0

•

**BMJ** Open

3	
4	
5 6	
7	
8 9	
9 10	
11	
12 13	
14	
15	
16 17	
18	
19	
20 21	
22	
23	
24 25	
26	
27 28	
20	
30	
31 32	
33	
34 25	
35 36	
37	
38 39	
40	
41	
42 43	
44	
45 46	
40 47	
48	
49 50	
51	
52	
53 54	
55	
56 57	
58	
59	
60	

#### 1 INTRODUCTION

2 The Coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, presents unprecedented 3 challenges for infection prevention and control (IPC) within healthcare facilities worldwide.<sup>1</sup> 4 Transmission may occur via respiratory droplets, fomites, or via airborne routes (following aerosol-5 generating procedures).<sup>2-4</sup> Prolonged indoor contact increases transmission, and nosocomial 6 transmission is common.<sup>5,6</sup> Respiratory isolation capacity (neutral or negative pressure side-rooms) 7 is easily saturated within healthcare facilities.<sup>1</sup> Decisions to isolate patients in need of admission 8 with suspected or possible COVID-19 must be rapid and accurate to maintain patient flow from 9 emergency departments (EDs), yet minimise risk of nosocomial transmission.

10

11 As COVID-19 can present with non-specific symptoms, diagnostic confirmation is often sought by 12 detection of SARS-CoV-2 ribonucleic acid (RNA) by reverse transcription-polymerase chain reaction 13 (RT-PCR) from nasopharyngeal swab (NPS).<sup>7</sup> However, decisions about patient isolation from the ED 14 are usually required before the results of RT-PCR assays are available.<sup>8,9</sup> Even near-patient, rapid RT-15 PCR platforms with assay run times of 1-2 hours can be quickly overwhelmed, especially during 16 peaks of COVID-19 incidence.<sup>10,11</sup> Multivariable diagnostic risk models, including clinical criteria and 17 thoracic imaging, are not sufficient, but may be useful as a triage test to ration expensive or scarce 18 point-of care assays.<sup>12,13</sup>

19

20 FebriDx (Lumos diagnostics, Sarasota, Florida, US) is a lateral flow assay that detects two host 21 response proteins, Myxovirus resistance protein A (MxA, positive if >40ng/mL) and C-reactive 22 protein (CRP, positive if >20mg/L) in capillary blood samples. MxA is an interferon-induced antiviral 23 host response protein that has been studied as a biomarker to differentiate bacterial and viral respiratory infections.<sup>14–17</sup> More recently FebriDx has demonstrated a sensitivity of 93% and 24 25 specificity of 86% for detecting COVID-19 compared to RT-PCR in hospital inpatients including 26 patients with clinically likely COVID-19 and those without symptoms of COVID-19.<sup>18</sup> FebriDx could be

#### **BMJ** Open

useful as an early triage tool to identify patients with COVID-19 and help guide isolation and IPC in
patients needing admission to hospital.<sup>18-21</sup> We therefore developed and implemented a COVID-19
triage algorithm, supported by FebriDx, to inform patient flow from the ED whilst awaiting RT-PCR
results. Here we describe the diagnostic performance of this algorithm compared to SARS-CoV-2 RTPCR. We also describe the impact on isolation room demand and the time to FebriDx and RT-PCR
results.

- 8 METHODS

#### 9 Patient cohort

We utilised data prospectively entered into a COVID-19 triage database and retrospective extraction
of clinical and bed allocation data from electronic patient records and hospital IT systems at
Northwick Park Hospital, a large district general hospital serving a diverse population in North-West
London. Patients were included if they required admission to a medical ward from the ED between
10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 inclusive and had a valid SARS-CoV-2 RT-PCR result on
admission.

#### 17 Triage Algorithm

On initial assessment in the ED, consecutive medical admissions were categorised by the attending clinician into three categories for their likelihood of COVID-19 (unlikely, possible and likely), using clinical criteria such as clinical history, observations and plain chest radiograph based on Public Health England guidance (Table 1 and Supplementary Table 1).<sup>22</sup> Patients discharged home or admitted under specialties other than medicine and those under sixteen years of age were not triaged using the algorithm and did not receive FebriDx testing, therefore their exclusion is unlikely to be a source of ascertainment bias. Patients with epidemiological risk factors for COVID-19 (eg. recent contact with a COVID-19 case or travel to a high-risk country) were triaged as likely COVID-19. We refer to this stage of the triage algorithm as 'clinical criteria'.

BMJ Open

2		
3	1	
4 5 6	2	We evaluated the impact of using FebriDx in a test-to-deisolate strategy amongst patients
7 8	3	designated as possibly having COVID-19 after clinical criteria had been applied at initial assessment.
9 10 11	4	Patients in the possible group underwent testing with FebriDx unless they declined or met an
12 13	5	exclusion criterion. Patients were excluded from FebriDx testing if they were immunosuppressed or
14 15	6	had had symptoms of COVID-19 for more than 10 days (in these situations a measurable Type I or
16 17 18	7	Type III interferon response might not be present in infected individuals, as per manufacturer's
19 20	8	guidance). Patients were also excluded if they had a previous diagnosis of COVID-19 (self-reported or
21 22	9	confirmed) or required high dependency unit or intensive care unit (HDU/ICU) admission due to the
23 24 25	10	greater infection control consequences of incorrect triage. All patients underwent NPS testing with
23 26 27	11	SARS-CoV-2 RT-PCR, with rapid RT-PCR assays being prioritised for patients in the likely group.
28 29	12	
30 31	13 14	Only patients with confirmed COVID-19 on SARS-CoV-2 RT-PCR were admitted to a COVID-19 cohort
32 33 34	15	area ('COVID ward'). Those triaged as likely, and those triaged as possible with a positive FebriDx or
35 36	16	excluded from having a FebriDx test were designated 'Triage Positive' and admitted to an isolation
37 38	17	room until PCR results were available. Patients assigned to the unlikely COVID-19 group and those
39 40 41	18	with a negative FebriDx test were designated 'Triage Negative' and admitted to 'non-COVID wards'
42 43	19	whilst awaiting SARS-CoV-2 RT-PCR results (Table 1 and Figure 1).
44 45	20	
46 47 48	21	Ethics Approval
49 50	22	FebriDx testing was implemented as part of routine clinical care in response to data on assay
51 52	23	performance for COVID-19 and an urgent clinical need. <sup>21</sup> The study was approved by the London
53 54	24	North West University Hospitals Trust Research and Development Committee (SE20/069), and given
55 56 57	25	this was a retrospective review using routinely collected clinical data, they deemed formal ethical
58 59 60	26	approval was not required. Results are reported in compliance with STARD and STROBE guidelines

3	
4	
5	
6	
6 7	
8	
0	
9 10	
10	
11	
12	
13	
14	
15	
16	
17	
11 12 13 14 15 16 17 18 19	
19	
20	
20	
21	
22	
23	
24	
25	
26	
27	
20 21 22 23 24 25 26 27 28	
29	
30	
31	
37	
32 33 34 35	
22	
34	
35	
36 37 38	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
55	
50 57	
58	
59	

4

(see supplementary materials). The FebriDx tests were purchased independently from a UK
 distributer, and the manufacturer had no role in the study conception, design, data analysis or
 manuscript preparation.

5 **Testing procedures and definitions** 

6 The FebriDx assay was performed as per the manufacturer's instructions at the point-of-care by 7 trained ED health-care assistants. In brief, 5µL of capillary blood is placed on the sample window and 8 reagents are released by pressing a button. The result is read after 10 minutes, with a positive result 9 being the presence of a blue line in the control window and a red line in the MxA window (limit of 10 detection 40ng/ml). The results from the CRP window were not used given all patients had 11 laboratory CRP measurements. Staff performing FebriDx had access to clinical information but not 12 SARS CoV-2 RT-PCR results at the time of FebriDx testing. Routine SARS CoV-2 RT-PCR was done on 13 NPS using either the Panther Fusion SARS-CoV-2 (Hologic Inc, CA, USA), Abbott RealTime SARS-CoV-2 14 (Abbott Park, IL, USA) or an extraction-free SARS-CoV-2 RT-PCR assay developed by Health Services 15 Laboratories (HSL), UK.<sup>23</sup> Rapid RT-PCR assays used were Xpert Xpress SARS-CoV-2 (Cepheid, CA, 16 USA) or SAMBA II SARS-CoV-2 (Diagnostics for the Real World, CA, USA). 17 Patients were defined as having COVID-19 or not based on the first valid RT-PCR result up to 72 18 19 hours after admission. Patients without a valid RT-PCR result or triage status were excluded from the 20 analysis. Vital signs, including National Early Warning Score (NEWS) were recorded on arrival to the 21 ED. All biochemical, haematological and radiological data were from the first results within 48 hours 22 of admission. Thoracic imaging (chest radiographs and CT) were reported and coded based upon

- 23 guidelines on COVID-19 from the British Society of Thoracic Imaging (BSTI) at the time of reporting
- by radiologists.<sup>24</sup> Vital status is reported at the time of hospital discharge or data extraction (20<sup>th</sup>
- 25 November 2020) for those who were still inpatients.
- <sup>59</sup> 26

Page 9 of 36

1 2 BMJ Open

3	
Δ	
د د	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	
/	
8	
9	
10	
11	
12	
13	
11	
15	
10	
10	
17	
18	
19	
20	
21	
22	
23	
24	
25	
25	
20	
27	
28	
29	
30	
31 32 33	
32	
33	
3/	
25	
22	
33 34 35 36 37 38	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
54 55	
56	
57	
58	
59	
60	

1 Data Analysis and Statistical	Methods
---------------------------------	---------

2 We evaluated the real-world diagnostic performance (sensitivity, specificity, and positive and 3 negative predictive values with 95% confidence intervals) of the triage algorithm (described above 4 and in Figure 1) using both clinical criteria (described above and in Table 1) and the FebriDx assay in 5 combination compared to SARS-CoV-2 RT-PCR from a single NPS as a reference standard. We also 6 evaluated each stage of the triage algorithm independently, estimating measures of diagnostic 7 performance for triage using clinical criteria alone and the FebriDx assay in patients with possible 8 COVID-19 compared to a SARS-CoV-2 RT-PCR reference standard. Patients with missing RT-PCR or 9 those missing data on triaging were excluded from analysis. We also reported the time from arrival 10 to FebriDx and RT-PCR results. We described the proportion of patients with COVID-19 who were 11 correctly isolated, estimated the number of isolation beds made available by FebriDx testing, and 12 described the patients with COVID-19 who were incorrectly triaged by the algorithm. Basic 13 descriptive statistics were performed, with comparisons made using chi-squared tests for 14 proportions, t-tests for means and Wilcoxon rank sum to compare non-normally distributed 15 populations. Logistic regression was used to compare age and sex adjusted estimates of in-hospital 16 death in each triage group, using complete cases only. Statistical analyses were performed using 17 Stata version 14.0 (StataCorp, LLC, College Station TX). Based on an anticipated sensitivity of 93%, a 18 sample size of 3335 would estimate the sensitivity of the triage algorithm  $\pm 5\%$  with alpha 0.05 and 19 prevalence of 3%.

20

60

#### 21 Patient and Public Involvement

There was no patient involvement in the development of the research question, study design orconduct of the study.

3	1	RESULTS
4 5		
6	2	Baseline characteristics and COVID-19 diagnosis
7		
8	3	Between the 10 <sup>th</sup> August and 4 <sup>th</sup> November 2020, there were 9,645 emergency department visits
9		
10	4	resulting in further hospital care. Of these, 3,433 (35.6%) were adult medical patients admitted for
11		
12 13	5	further treatment, were triaged using the algorithm based on COVID-19 status and had a valid SARS-
14		
15	6	CoV-2 RT-PCR result (figure 1). 175 (5.1%) patients were triaged as likely COVID-19, 2,033 (59.2%)
16	_	
17	7	patients as unlikely COVID-19 and 1,225 (35.7%) patients were triaged into the possible COVID-19
18		
19 20	8	category. Key patient characteristics are given in Table 2.
20		
22	9	
23		
24	10	There were several differences between the three triage groups (Table 2). The likely COVID-19 group
25	11	
26 27	11	were younger, had higher NEWS scores on arrival and more frequently required supplemental
28	12	$\alpha$ and $\alpha$ and $\alpha$ and $\alpha$ and $\alpha$ are the second to the second to $(\alpha, \beta, 0, 0)$ for all comparisons). As
29	12	oxygen compared to the unlikely group and the possible group (p<0.02 for all comparisons). As
30	13	expected, more patients in the likely COVID-19 group had chest radiograph changes typical for
31	15	expected, more patients in the likely COVID-19 group had chest radiograph changes typical for
32	14	COVID-19 than in the possible (p<0.001), and the unlikely COVID-19 group (p<0.001). The possible
33 34	11	
35	15	COVID-19 group were older than the other two groups and were more likely to have an elevated
36		
37	16	neutrophil count than the likely or possible groups.
38		
39 40	17	
40		
42	18	Overall, 136/3,443 admissions (4.0%) were diagnosed with PCR-confirmed COVID-19. Prevalence of
43		
44	19	COVID-19 was 46% (80/175) in likely patients, and 4.1% (50/1,225) in the possible group. Of those
45 46		
46 47	20	triaged as unlikely COVID-19, only 6/2,033 (0.3%) were SARS-CoV-2 RT-PCR positive.
48		
49	21	
50		
51	22	Performance of FebriDx and triage algorithm
52	•••	
53 54	23	The overall diagnostic performance of the clinical triage algorithm compared to the reference
55	24	
56	24	standard of SARS-CoV-2 RT-PCR is summarised in table 3. 958 (78.2%) patients in the possible group
57	25	were tested using FebriDx (those excluded are detailed in figure 1). 13.8% (132/958) of FebriDx test
58 50	23	were tested using redrive (those excluded are detailed in figure 1). 13.8% (132/938) OF FEDRIDX LESL
59 60	26	results were positive for MxA, with 86.2% negative and no invalid results. The median duration of
~~	-0	resards there positive for this y that coizy hebutive and no invalid results. The inculair datafor of

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

3 4	1	COVID-19 symptoms in patients tested by FebriDx was 2 days (IQR 1-3, n=847). Patients with positive
5 6	2	FebriDx results were younger, more likely to be febrile and less likely to have raised neutrophil
7 8	3	counts than FebriDx negative patients (supplementary table 2).
9 10 11	4	
12 13	5	31% (41/132) of patients with a positive FebriDx had a positive SARS-CoV-2 RT-PCR, whilst only
14 15	6	4/826 (0.5%) with a negative FebriDx were diagnosed as having COVID-19. All 4 patients with false-
16 17 18	7	negative FebriDx results had normal chest radiographs. 2 patients tested negative for COVID-19 by
19 20	8	SARS-CoV-2 RT-PCR but had positive FebriDx results and chest radiograph appearances typical for
21 22	9	COVID-19. In the possible COVID-19 group, FebriDx results were available a median of 2.2 hours
23 24	10	(IQR: 1.4 to 3.1, n=808) and RT-PCR results a median of 17.8 hours (IQR: 11.4 – 25.3, n=456) after
25 26 27	11	arrival to the ED (figure 2). 88.0% of FebriDx results were available within 4 hours of arrival (n=808).
28 29	12	
30 31	13	The triage algorithm correctly identified 126/136 patients with PCR-confirmed COVID-19 in the likely
32 33	14	group (sensitivity 93%, 95%CI: 87 - 96) (table 3). The 10 patients who were SARS-CoV-2 RT-PCR
34 35	15	positive but missed by the triage algorithm are described in supplementary table 3. 6/10 were
36 37	16	classified as unlikely, and 4/10 were classified as possible COVID-19 and had a negative FebriDx. 2/10
38 39 40	17	were febrile on admission, none required supplemental oxygen, length of stay was short (median 2
41 42	18	days) and 8 had normal chest radiographs (2 did not have thoracic imaging done). Specificity of the
43 44	19	algorithm was 86.4% (85.2 - 87.5), and negative predictive value was 99.7% (99.4 - 99.8). Although
45 46	20	changes were made to clinical triage criteria during the study period (supplementary table 1), our
47 48 49	21	estimates of diagnostic performance were comparable after excluding individuals who arrived
49 50 51	22	before the last alteration (supplementary table 4).
52 53	23	
54 55 56	24	Outcomes
57 58	25	95% (129/136) of patients with COVID-19 were appropriately managed in isolation rooms or COVID
59 60	26	cohort wards as a result of the triage algorithm (supplementary table 5). Of the 10 patients with

#### **BMJ** Open

PCR-confirmed COVID-19 not identified by the triage algorithm, 7 were initially managed in a non-COVID ward. Had all patients been isolated until SARS-CoV-2 RT-PCR result was available (ie without using clinical criteria or FebriDx to de-isolate) 2,859 more isolation rooms would have been used.
When using the triage algorithm, clinical criteria allowed 2,033 patients to be released from isolation after being classified as unlikely COVID-19. The addition of FebriDx to clinical triage allowed 826 more patients to be managed in 'non-COVID' wards than if all patients triaged possible COVID-19 had required isolation (9.5 isolation rooms saved per day, 95%CI: 8.9 – 10.2).

9 11 (8%) patients with COVID-19 died compared to 150 (4.5%) without COVID-19 (p=0.042). Age and
10 sex adjusted odds of death during the admission were higher for patients in the likely (OR: 3.42, 95%
11 CI: 1.81 - 6.45) and possible groups (OR: 2.44, 95% CI: 1.73 - 3.44) than the unlikely COVID-19 group.

RELEX ONL

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open

#### 1 DISCUSSION

Our main findings are that a pragmatic triage algorithm using simple clinical parameters available
within the ED and the FebriDx point-of-care test had good sensitivity (93%) and excellent NPV
(99.7%) for COVID-19 diagnosed by RT-PCR. Inclusion of FebriDx improved the specificity of triage
with minimal reductions in sensitivity, allowing a substantial reduction in the number of isolation
rooms needed.

Although clinicians were able to identify patients likely and unlikely to have COVID-19 (46% and 0.3% of whom had confirmed COVID-19 respectively) based on clinical assessment, radiology and basic blood tests, their assessment was not sufficiently specific. The group of patients identified as 'possible' COVID-19 had a 4% prevalence of COVID-19, high mortality and was large enough to overwhelm isolation room capacity. We demonstrate a simple, rapid test performed at the point-of-care can help further risk stratify this group. In real-life settings in a busy ED, a point-of-care test was able to inform isolation decisions within 4 hours of arrival compared to PCR results which were too slow to inform patient flow from ED, even when using 'rapid' PCR assays. Although formal cost-effectiveness analysis was not performed, each FebriDx test only costs about US\$18, and this may lead to cost savings.

The strengths of this study are its pragmatic design under routine clinical settings, and that we are able to account for over 95% of medical admissions, reducing risks of bias. There are, however, several limitations. A single SARS-CoV-2 RT-PCR is an imperfect reference standard, and does not account for RT-PCR negative COVID-19 patients. We used multiple RT-PCR platforms, which will have different PCR targets and performance. 10% of patients in the possible group did not get tested with FebriDx for unclear reasons, which could be a source of bias unless these were unavoidable random losses in a busy ED department. The prevalence of COVID-19 was 4.0% in this cohort, and it is 

Page 14 of 36

**BMJ** Open

> unclear what impact a higher prevalence of COVID-19 or other respiratory pathogens such as influenza would have on these findings. The criteria for likely and possible COVID-19 groups changed during the study period, although this is unlikely to significantly alter the outcomes. These data build on previous studies of FebriDx showing good sensitivity, and utility as a 'rule-out' test for COVID-19.<sup>17–20</sup> In our pragmatic, 'real-world' study clinical triage by ED clinicians was imperfect. For example, two PCR positive patients were incorrectly classified as 'unlikely' COVID-19 given they had a temperature of >38°C on arrival (supplementary table 3). The estimate of sensitivity of FebriDx for detecting COVID-19 in our cohort is lower than previously described, likely because our testing strategy differs in that it does not include patients deemed likely to have COVID-19 by clinical criteria. Testing this group would have been unlikely to alter clinical decisions, even if FebriDx had been negative, given the high pre-test probability. The FebriDx test allowed patients with possible COVID-19 to be divided into two groups with similar characteristics and clinical features, but vastly different COVID-19 prevalence (0.5% in FebriDx negative, and 31% in FebriDx positive). However, about 10% of patients in this group were not eligible for FebriDx testing, and had to be managed in isolation rooms as triage-positive patients (see Figure 1). Only ten patients with COVID-19 were incorrectly triaged by the algorithm, four of whom were tested and 'missed' using FebriDx. These patients were younger, less symptomatic, did not have chest radiograph changes, and mostly likely had mild or asymptomatic COVID-19 infection. Given that MxA is an intracellular GTPase induced by type I and type III interferon responses, it is plausible that sensitivity would be lower in oligo- or asymptomatic infection.<sup>25</sup> Although the patients missed by the algorithm are potential sources of nosocomial transmission, asymptomatic disease is thought to be less transmissible.<sup>26</sup> We found no nosocomial cases related to these patients.

2		
3 4	1	In conclusion, we demonstrate that a simple triage system including the novel FebriDx point-of-care
5 6	2	test had good sensitivity and negative predictive value for COVID-19 and utility for managing medical
7 8	3	admissions from the ED.
9 10	1	
11	4 5	
12	6	Acknowledgements
13 14	0	Acknowledgements
15 16	7	We would like to acknowledge to all the clinical staff at Northwick Park Hospital who cared for the
17 18	8	patients involved in this study. In particular, we give thanks to the point-of-care team for their
19 20	9	outstanding work in establishing and running the new point-of-care testing service in the emergency
21 22 23	10	department.
23 24 25	11	
26 27	12	Funding statement
28 29 30	13	This research received no specific grant from any funding agency in the public, commercial or not-
31 32	14	for-profit sectors.
33 34	15	
35 36 27	16	Author contributions
37 38 39	17	HH, AGW, LJ, SF, JBL, JR, N Vaughan, N Vaid, GGR, and AKA made substantial contribution to the
40 41	18	conception of the work. HH, AGW, LJ, and GD made substantial contribution to the design of the
42 43	19	work. HH, GD, SN, KS, SP, MGD, and MT contributed to data acquisition. HH and AGW analysed the
44 45	20	data. HH, AGW and LJ contributed to data interpretation. HH and AGW drafted the manuscript. All
46 47 48	21	authors contributed to revising the manuscript critically for important intellectual content, approved
49 50	22	the final manuscript and are accountable for all aspects of the work.
51 52	23	
53 54	24	Competing interests statement
55 56 57	25	The authors have no competing interests to declare.
57 58 59	26	
60	27	Data availability statement

2 3 4	1
5	2
6 7 8	3
9 10	4
11 12 13	5
14 14 15 16 17 18 19 20 21 22 32 4 25 26 27 28 29 30 31 22 33 4 35 36 37 38 39 40 41 42 43 44 50 51 52 53 45 56 57 58 59 60	$\begin{array}{c} 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ \end{array}$

1 Data are available upon reasonable request, subject to approval by the London North West

- 2 University Healthcare NHS Trust Research and Governance Department and approval from relevant
- 3 ethics and regulatory bodies.

# 5 <u>References:</u>

- Verelst F, Kuylen E, Beutels P. Indications for healthcare surge capacity in European
  countries facing an exponential increase in coronavirus disease (COVID-19) cases,
  March 2020. Euro Surveill. 2020 Apr;25(13):2000323. doi: 10.2807/15607917.ES.2020.25.13.2000323.
- 102Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and11innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract12and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med132020;8:687–95. doi:10.1016/S2213-2600(20)30193-4
- I4 3 Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air
   contamination in an acute healthcare setting during the peak of the COVID-19
   pandemic in London. *Clin Infect Dis* Published Online First: 8 July 2020.
   doi:10.1093/cid/ciaa905
- van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of
   SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med* 2020;382:1564–7.
   doi:10.1056/nejmc2004973
- 3215Cevik M, Marcus JL, Buckee C, et al. Severe Acute Respiratory Syndrome Coronavirus42222 (SARS-CoV-2) Transmission Dynamics Should Inform Policy. Clin Infect Dis Published523Online First: 23 September 2020. doi:10.1093/cid/ciaa1442
- Rickman HM, Rampling T, Shaw K, et al. Nosocomial Transmission of Coronavirus
   Disease 2019: A Retrospective Study of 66 Hospital-acquired Cases in a London
   Description
   D
- 11<br/>12287Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with13292019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA J Am Med1430Assoc 2020;323:1061–9. doi:10.1001/jama.2020.1585
- <sup>45</sup> 31 8 Brendish NJ, Poole S, Naidu V V., et al. Clinical impact of molecular point-of-care
  <sup>46</sup> 32 testing for suspected COVID-19 in hospital (COV-19POC): a prospective,
  <sup>47</sup> 33 interventional, non-randomised, controlled study. *Lancet Respir Med* 2020;8:1192–
  <sup>49</sup> 34 200. doi:10.1016/S2213-2600(20)30454-9
- 50359NHS England. Pillar 1 NHS labs COVID-19 testing turnaround time data: 15 July 2020.51362020. https://www.england.nhs.uk/coronavirus/publication/nhs-labs-covid-19-5237testing-turnaround-time-data/
- 3810Gibani MM, Toumazou C, Sohbati M, et al. Assessing a novel, lab-free, point-of-care39test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. The Lancet Microbe402020;1:e300-7. doi:10.1016/s2666-5247(20)30121-x
- 41 11 Collier DA, Assennato SM, Warne B, et al. Point of Care Nucleic Acid Testing for SARS 42 CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study.
   43 Cell Reports Med 2020;1. doi:10.1016/j.xcrm.2020.100062

1			
2 3			
4	1	12	Fink DL, Khan PY, Goldman N, et al. Development and internal validation of a
5	2		diagnostic prediction model for COVID-19 at time of admission to hospital. <i>QJM An</i>
6	3	10	Int J Med Published Online First: 9 November 2020. doi:10.1093/qjmed/hcaa305
7 8	4 5	13	Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and
9	5 6		prognosis of covid-19: Systematic review and critical appraisal. <i>BMJ</i> 2020;369:18. doi:10.1136/bmj.m1328
10	7	14	Engelmann I, Dubos F, Lobert PE, et al. Diagnosis of viral infections using myxovirus
11 12	8	14	resistance protein a (MxA). <i>Pediatrics</i> 2015;135:e985–93. doi:10.1542/peds.2014-
12	9		1946
14	10	15	Nakabayashi M, Adachi Y, Itazawa T, et al. MxA-based recognition of viral illness in
15	11	10	febrile children by a whole blood assay. <i>Pediatr Res</i> 2006;60:770–4.
16 17	12		doi:10.1203/01.pdr.0000246098.65888.5b
18	13	16	Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care
19	14		immunoassay to identify viral and/or bacterial immune response in patients with
20	15		acute febrile respiratory infection. <i>Eur Clin Respir J</i> 2015;2:28245.
21 22	16		doi:10.3402/ecrj.v2.28245
23	17	17	Thomas J, Pociute A, Kevalas R, et al. Blood biomarkers differentiating viral versus
24	18		bacterial pneumonia aetiology: A literature review. Ital. J. Pediatr. 2020;46:4.
25	19		doi:10.1186/s13052-020-0770-3
26 27	20	18	Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host
28	21		response point-of-care test in patients hospitalised with suspected COVID-19. J Infect
29	22		2020;81:607–13. doi:10.1016/j.jinf.2020.06.051
30 31	23	19	Karim N, Ashraf MZ, Naeem M, et al. Utility of the FebriDx point-of-care test for rapid
32	24		triage and identification of possible coronavirus disease 2019 (COVID-19). Int J Clin
33	25		Pract Published Online First: 17 September 2020. doi:10.1111/ijcp.13702
34	26	20	National Institute for Health and Care Excellence. Overview   FebriDx for C-reactive
35 36	27		protein and myxovirus resistance protein A testing   Advice   NICE.
37	28	24	https://www.nice.org.uk/advice/mib224/ (accessed 19 Dec 2020).
38	29	21	Ismail SA, Huntley C, Post N, et al. Horses for courses? Assessing the potential value of
39	30		a surrogate, point-of-care test for SARS-CoV-2 epidemic control. <i>Influenza Other Respi</i>
40 41	31 32	22	<i>Viruses</i> 2020;00:1– 4. doi:10.1111/irv.12796 Public Health England. (2020, June 18) COVID-19: infection prevention and control
42	32 33	22	guidance. Retrieved from:
43	33 34		https://www.publichealth.hscni.net/sites/default/files/2020-10/COVID-
44 45	35		19 Infection prevention and control guidance complete. 3.2
45 46	36		%2818 06 2020%29 0.pdf (accessed 19 Dec 2020)
47	37	23	Grant P, Turner M, Shin GY, et al. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by
48	38	23	RT-PCR to increase capacity for national testing programmes during a pandemic.
49 50	39		<i>bioRxiv</i> [Preprint] Published Online First: 9 April 2020.
51	40		doi:10.1101/2020.04.06.028316
52	41	24	British Society of Thoracic Imaging. BSTI COVID-19 CXR Report Proforma.
53	42		https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUK
54 55	43		Ewj_j4CurtrtAhUnQUEAHRTWA80QFjABegQIARAC&url=https%3A%2F%2Fwww.bsti.o
56	44		rg.uk%2Fmedia%2Fresources%2Ffiles%2FBSTI_COVID_CXR_Proforma_v.3-
57	45		1.pdf&usg=AOvVaw0vUxoui2fz68LEbrs6eTQm
58	46	25	Shirley M. FebriDx <sup>®</sup> : A Rapid Diagnostic Test for Differentiating Bacterial and Viral
59 60	47		Aetiologies in Acute Respiratory Infections. Mol Diagnosis Ther 2019;23:803–9.

 doi:10.1007/s40291-019-00433-x

Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe 2020;0. doi:10.1016/s2666-5247(20)30172-5

## **Tables**

COVID- 19 triage category	Clinical Criteria	Diagnostics performed in ED	Bed Allocation from ED
	Recent Contact with a confirmed COVID-19 case OR Travel to High Risk country within the last 14 days	Routine RT-PCR	Isolation Room
Likely	Known COVID-19 illness confirmed within the last 14 days prior to current attendance		COVID-19 cohort ward or isolation room
	High Clinical Suspicion (eg. Oxygen Requirement, Bilateral infiltrates, Normal WCC/high CRP) OR Change in Normal sense of Smell or Taste	Urgent RT-PCR	Isolation Room
Possible	Clinical or Radiological Pneumonia OR	FebriDx * &	FebriDx Positive (or not done) → Isolation Room
Possible	Fever / Persistent Cough / Shortness of Breath / Hypoxia / Diarrhoea / Confusion	م Urgent RT-PCR	FebriDx Negative → Non-COVID ward
Unlikely	None of the Above	Routine RT-PCR	Non-COVID ward

Table 1. Clinical Criteria for determining triage groups, testing strategy and bed allocation from the Emergency Department prior to RT-PCR result. Clinical criteria for determining triage groups are

shown as of 08/10/2020. Changes to these criteria over time are detailed in supplementary table 1.

\* Patients were excluded from FebriDx testing if they had a prior history of COVID-19, were

immunosuppressed, required intensive care or high dependency unit admission, or had had COVID-

19 symptoms for > 10 days. RT-PCR=Reverse transcription polymerase chain reaction,

ED=Emergency department

1	
2	
3	
4	
-	
5	
6	
7	
,	
8	
9	
10	
10	
11	
12	
12	
15	
14	
15	
14	
10	
17	
3         4         5         6         7         8         9         10         11         12         13         14         15         16         17         18         20         21         23         24         25         26         27         28	
10	
19	
20	
21	
22	
22	
23	
24	
25	
25	
26	
27	
28	
20	
29	
29 30	
31	
22	
32	
33	
34	
27	
32 33 34 35 36 37	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
16	

Variable	Unlikely	Possible	Likely
Ν	2033	1225	175
Age (years) median (IQR)	69 (49, 82)	75 (60, 84)	62 (48, 74)
Age over 65 years, n (%, 95%Cl)	1128 (55.5%, 53.3; 57.6)	846 (69.1%, 66.5; 71.6)	79 (45%, 38; 5
Female Sex, n (%, 95%Cl)	969 (47.7%, 45.5; 49.8)	603 (49.2%, 46.4; 52.0)	72 (41%, 34; 4
Male Sex, n (%, 95%Cl)	1064 (52.3%, 50.2; 54.5)	622 (50.8%, 48.0; 53.6)	103 (59%, 52; 6
NEWS, median (IQR)	1 (0, 3)	4 (2, 6)	5 (3, 7)
Respiratory Rate (breaths/min), median (IQR)	18 (18, 20)	24 (20, 28)	24 (21, 32)
SpO2 <94%, n (%, 95%Cl)	61 (3.1%, 2.4; 3.9)	234 (19.5%, 17.3; 21.8)	38 (22%, 17; 2
Required Supplemental Oxygen, n (%, 95%CI)	52 (2.7%, 2.0; 3.4)	245 (20.4%, 18.1; 22.7)	52 (30%, 24; 3
Temperature >37.5ºC, n (%, 95%Cl)	172 (8.8%, 7.6; 10.1)	359 (30.0%, 27.4; 32.6)	73 (43%, 35; 5
Chest Radiograph - Normal, n (%, 95%CI)	1171 (81.0%, 79.0; 83.0)	537 (49.9%, 46.9; 52.9)	42 (30%, 22; 3
Chest Radiograph - Typical for COVID-19, n (%, 95%CI)	4 (0.3%, 0.0; 0.5)	25 (2.3%, 1.4; 3.2)	54 (38%, 30; 4
Chest Radiograph - Other, n (%, 95%Cl)	271 (18.7%, 16.7; 20.8)	514 (47.8%, 44.8; 50.8)	45 (32%, 24; 4
Chest CT - Normal, n (%, 95%Cl)	8 (24%, 12; 41)	9 (16%, 9; 29)	0 (0%, 0; 0)
Chest CT - Typical for COVID-19, n (%, 95%Cl)	0 (0%, 0; 0)	3 (5%, 2; 16)	3 (43%, 10; 8
Chest CT - Other, n (%, 95%CI)	26 (76%, 59; 88)	43 (78%, 65; 87)	4 (57%, 17; 90
CRP (mg/L), median (IQR)	5.7 (1.4, 26.9)	26.4 (7.05, 87.65)	53.7 (25.9, 122
CRP >20mg/L, n (%, 95%Cl)	545 (28.7%, 26.7; 30.7)	656 (55.8%, 52.9; 58.6)	134 (80%, 74;
Lymphocyte Count <1.0x10^9/l, n (%, 95%Cl)	373 (25.3%, 23.1; 27.5)	383 (43.9%, 40.6; 47.2)	70 (55%, 46; 6
Neutrophil Count >7.5x10^9/l, n (%, 95%Cl)	620 (32.0%, 29.9; 34.0)	598 (50.4%, 47.6; 53.3)	61 (36%, 29; 4
Crude In Hospital Mortality, n (%, 95%CI)	57 (2.8%, 2.1; 3.6)	89 (7.5%, 6.0; 9.0)	13 (8%, 4; 12
SARS-CoV-2 RNA Detectable on RT-PCR, n (%, 95%CI)	6 (0.3%, 0.1; 0.5)	50 (4.1%, 3.0; 5.2)	80 (46%, 38; 5

**Table 2: Baseline characteristics, vital signs, initial investigations, mortality and SARS-CoV-2 RT-PCR results for patients in the unlikely, possible and likely COVID-19 groups.** For observations on arrival, 3.2 to 4.1% of data were missing. Data were missing for 5.5% of CRP results and 4.0% of haematology results, 22.4% of chest radiograph reports and 2.1% of vital status. 96 patients (2.8%) had a chest CT report available. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Typical; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19. Chest CT

reports were coded as: CVCT0= Normal; CVCT1= Typical; CVCT2= Indeterminate; CVCT3= Non-COVID-19. IQR=Inter-guartile range, CI=Confidence Interval, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, CT=Computerised Tomography

 .- Indetermina. .uons, CRP=C-Reactive.

		SARS-0	<u></u>		
А		Positive	Negative	Total	
	Likely or Possible COVID-19	130	1270	1400	PPV: 9.3% (95% CI: 7.9 – 10
Clinical criteria alone (without FebriDx) (n=3433)	Unlikely COVID-19	6	2027	2033	NPV: 99.7% (95% CI: 99.3 – 99
	Total	136	3297	3433	(95% Cl. 99.3 - 9
		Sensitivity 96% (95% Cl: 91 – 98)	Specificity 61.5% (95% CI: 59.8 – 63.1)		J
		~			
		SARS-0	CoV-2 RT-PCR		
В		Positive	Negative	Total	
FebriDx alone in the possible	FebriDx Positive	41	91	132	PPV: 31% (95% CI: 24 – 39
COVID-19 group with FebriDx done. (n=958)	FebriDx Negative	4	822	826	NPV: 99.5% (95% CI: 98.7 – 99
	Total	45	913	958	
		Sensitivity 91% (95% Cl: 78 – 97)	Specificity 90.0% (95% CI: 87.9 – 91.8)		,
		SARS-0	CoV-2 RT-PCR		
С		Positive	Negative	Total	
Triage Algorithm	Triage Positive	126	448	574	PPV: 22% (95% CI: 19 - 26
using clinical criteria and FebriDx (n=3433)	Triage Negative	10	2849	2859	NPV: 99.7% (95% CI: 99.4 - 99
	Total	136	3297	3433	
		Sensitivity 93% (95% Cl: 87 - 96)	Specificity 86.4% (95% CI: 85.2 - 87.5)		-

**BMJ** Open

Table 3 Cross tabulation of results of the triage algorithm with and without

FebriDx as well as the results of FebriDx within the possible COVID-19 group compared to a SARS-CoV-2 RT-PCR reference standard. Measures of Diagnostic Performance are presented for the triage algorithm for the detection of COVID-19: 3A) Using clinical criteria alone without FebriDx, where subjects are classified as positive or negative based on clinical criteria shown in Table 1. Subjects were 'positive' if they were assigned as likely or possible COVID-19 based on clinical criteria alone. 3B) Using the FebriDx assay alone within the possible COVID-19 group receiving a FebriDx test. Subjects are classed as FebriDx positive or negative based on the FebriDx test only. 3C) Using clinical criteria supported by the FebriDx assay. Subjects were classed as Triage positive or negative based on their flow through the algorithm as shown in figure 1. Patients were Triage positive if they ey were tric, itive Predictive v were triaged as likely COVID-19 or possible COVID-19 without a negative FebriDx result. Patients were Triage Negative if they were triaged as unlikely COVID-19 or possible COVID-19 with a negative FebriDx result. PPV = Positive Predictive Value, NPV = Negative Predictive Value, CI = Confidence Interval

#### Figure Legends:


#### Figure 1: Patient flow through the study and the COVID-19 triage algorithm


Patients were included if they required admission to a medical ward from the ED between 10<sup>th</sup> August 2020 and 4<sup>th</sup> November 2020 inclusive. Patients were excluded if they were under sixteen years of age, admitted under specialities other than medicine, or if their triage status or SARS-CoV-2 RT-PCR result was unknown. Counts at each stage of triage are shown in 2x2 tables on the right. These counts correspond with the 2x2 tables and measures of diagnostic performance shown in Table 3. PCR = SARS-CoV-2 RT-PCR.

#### Figure 2: Time from arrival to the availability of FebriDx and SARS-CoV-2 RT-PCR results

A e E pa gency de, JRT-PCR resu. .ime the SARS-Co Kernel frequency density plot using the Epanechniko function; Time to FebriDx result was calculated as the time from arrival to the emergency department until the time the FebriDx result was recorded (blue plot), bandwidth=0.3; Time to RT-PCR result was calculated as the time from arrival to to the emergency department until the time the SARS-CoV-2 RT-PCR result was recorded (red plot), bandwidth=2.

**BMJ** Open





# <u>Use of the FebriDx point-of-care assay as part of a triage algorithm for medical admissions with</u> possible COVID-19

#### Supplementary Tables:

# Supplementary Table 1: Changes made to the inclusion criteria for the triage categories and the exclusion criteria for FebriDx testing during the study period.

	Da	ate of Update to CC	VID-19 Triage Crite	eria				
	06/07/2020	09/09/2020	21/09/2020	08/10/2020				
		Confirmed COVID-19	during current illnes	S				
	(eg. Oxygen R	High Clinic equirement, Bilatera	al Suspicion Il infiltrates, Normal V	WCC/high CRP)				
Likoly	Rece	ent Contact with a c	confirmed COVID-1	9 case				
Likely	Trave	l to High Risk count	ry within the last 1	4 days				
				Change in Normal sense of Smell or				
				Taste				
	Change in N	ell or Taste						
	Clinical or Radiological Pneumonia							
Possible	Fever PLUS Persi	istent Cough OR						
	Shortness of Bre	eath OR Hypoxia Shortness of Breath OR Hypoxia						
		Confusion ( Diarrhoea						
Unlikely		None of t	the Above					
	Immunosuppressed							
Exclusion	Previous COVID-19							
Criteria for FebriDx		R	equiring ITU/HDU/	NIV				
COUDA			COVID-19 Sym	nptoms >10 days				

Supplementary Table 1 footnotes:

The inclusion criteria for the triage categories and the exclusion criteria for FebriDx testing were adjusted during the course of this pragmatic study. WCC=white cell count, CRP= C-Reactive Protein, ITU=Intensive Therapy Unit, HDU=High Dependency Unit, NIV=Non-Invasive ventilation.

 BMJ Open

Variable	FebriDx Negative	FebriDx Positive	FebriDx Not Done
Ν	826	132	267
Age (years) median (IQR)	77 (61, 85)	69.5 (54.5, 81.5)	72 (60, 81)
Age over 65 years, n (%, 95%Cl)	586 (70.9, 67.8; 74.0)	80 (61, 52; 69)	180 (67, 62; 73)
Female Sex, n (%, 95%Cl)	399 (48.3, 44.9; 51.7)	63 (48, 39; 56)	141 (53, 47; 59)
Male Sex, n (%, 95%Cl)	427 (51.7, 48.3; 55.1)	69 (52, 44; 61)	126 (47, 41; 53)
NEWS, median (IQR)	4 (2, 7)	4 (3, 6)	4 (2, 6)
Respiratory Rate (breaths/min), median (IQR)	24 (20, 28)	24 (20, 28)	24 (19, 28)
SpO2 <94%, n (%, 95%CI)	164 (20.2, 17.6; 23.1)	24 (19, 13; 26)	46 (18, 14; 23)
Required Supplemental Oxygen, n (%, 95%CI)	170 (20.9, 18.2; 23.8)	21 (16, 11; 24)	54 (21, 16; 26)
Temperature >37.5ºC, n (%, 95%Cl)	245 (30.2, 27.1; 33.4)	55 (43, 34; 51)	59 (23, 18; 29)
Chest Radiograph - Normal, n (%, 95%CI)	375 (51.2, 47.6; 54.9)	52 (43, 35; 52)	110 (49, 43; 56)
Chest Radiograph - Typical for COVID-19, n (%, 95%CI)	8 (1.1, 0.6; 2.2)	11 (9, 5; 16)	6 (3, 1; 6)
Chest Radiograph - Other, n (%, 95%Cl)	349 (47.7, 44.1; 51.3)	57 (48, 39; 57)	108 (48, 42; 55)
Chest CT - Normal, n (%, 95%CI)	9 (20, 10; 34)	0 (0)	0 (0)
Chest CT - Typical for COVID-19, n (%, 95%CI)	2 (4, 1; 17)	0 (0)	1 (17, 1; 81)
Chest CT - Other, n (%, 95%Cl)	35 (76, 61; 87)	3 (100)	5 (83, 19; 99)
CRP (mg/L), median (IQR)	26 (7, 96)	37.05 (17.1, 78.9)	18.85 (4.9, 76.3)
CRP >20mg/L, n (%, 95%CI)	443 (55.9, 52.5; 59.4)	87 (67, 58; 75)	126 (50, 43; 56)
Lymphocyte Count <1.0x10^9/l, n (%, 95%Cl)	263 (43.8, 39.9; 47.8)	46 (48, 38; 58)	74 (42, 35; 49)
Neutrophil Count >7.5x10^9/l, n (%, 95%Cl)	422 (52.8, 49.3; 56.3)	50 (38, 30; 47)	126 (49, 43; 55)
Mortality, n (%, 95%Cl)	65 (8.1, 6.4; 10.2)	6 (5, 2; 10)	18 (7, 4; 11)
SARS-CoV2 RNA Detectable on RT-PCR, n (%, 95%CI)	4 (0.5, 0.3; 1.3)	41 (31, 24; 40)	5 (2, 1; 4)

Supplementary Table 2: Baseline characteristics, vital signs, initial investigations, mortality and SARS-CoV-2 RT-PCR results for patients in the possible COVID-19 group by FebriDx test result

Supplementary Table 2 footnotes: Missing data are summarised in the footnotes to table 2 in the main text. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic; CVCX2 = Indeterminate; CVCX3 = Non-COVID-19. Chest CT reports were coded as: CVCT0= Normal; CVCT1= Classic/probable; CVCT2= Indeterminate; CVCT3= Non-COVID-19. IQR=Inter-quartile range, CI=Confidence Interval, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, CT=Computerised Tomography

. .

.

\_

\_

\_

\_

י ר	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
9 10 11 12 13 14 15 16	
16	
10	
17	
18	
19	
20	
21	
22	
23	
24	
25	
24 25 26	
27	
28	
29	
30	
31 32	
32 33	
33	
34	
34 35 36	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
Uτ	

1

# Supplementary Table 3: Baseline characteristics of patients with positive SARS-CoV-2 RT-PCR results who were classified as triage negative by the algorithm

.

~

Case	1	2	3	4	5	6	7	8	9	10
Triage Status	Unlikely						Possible, FebriDx Negative			
Decade of Life*	5	7	3	5	7	6	6	3	7	5
Sex (F/M)	F	М	F	М	М	М	F	М	F	F
Presentation	Fever and epigastric pain	Hypoglycaemic collapse	Hyperkalaemia on clinic bloods	Herpes Zoster	Intentional Overdose	Unstable Angina	URTI symptoms	Diarrhoea	Fever and SOB	Headache and anosmia
Duration of Symptoms (days)	х	x	x	x	х	х	5	7	1	2
NEWS on Arrival	4	1	0	1	2	1	7	2	3	3
Respiratory Rate (breaths/min)	20	18	18	20	14	18	32	18	22	21
SpO2 (%)	97	96	100	96	93	98	94	100	96	100
Required Supplemental Oxygen (Y/N)	Ν	Ν	N	N	N	N	N	N	Ν	Ν
Temperature <sup></sup>	38.1	35.2	36.5	38	36.9	37	39.7	38.3	38.1	36.3
Chest Radiograph	CVCX0	CVCX0	ND	CVCX0	CVCX0	CVCX0	CVCX0	ND	CVCX0	CVCX0
CRP (mg/L)	9.5	2.6	2.6	4	0.7	57.1	16.4	0.9	5.1	68.5
Lymphocyte Count (x10^9/l)	0.5	1.4	2.2	1.1	3	0.7	2.2	1.2	0.5	0.7
Neutrophil Count (x10^9/l)	8.8	9.5	6.5	2.9	2.5	1.9	6.7	2.7	4.6	1.6
Isolated (Y / N)	Ν	Ν	N	Y	N	N	N	Y	Y	Ν
ICU Admission (Y / N)	Ν	Ν	N	N	N	N	N	N	Ν	Ν
Died (Y / N)	Ν	Ν	Ν	N	N	Ν	N	N	Ν	Ν
Length of stay (days)	2	1	1	1	7	2	4	2	4	1

Supplementary Table 3 footnotes: \*Age on arrival is presented in terms of Decade of Life (eg. 5 = age 40 to 49 years).Duration of symptoms was recorded only for patients with a clinical syndrome compatible with COVID-19 tested by FebriDx. Observations presented are those measured on arrival to the Emergency Department. Imaging reports were coded as per BSTI guidelines. Chest Radiograph reports were coded as: CVCX0 = Normal; CVCX1 = Classic;

BMJ Open

3	CVCV2 - Indeterminates CVCV2 - Nen COVID 10, NEWS-National Early Warning Score, SpO2-Owygen Saturations, CRD-C Reactive Protein, V-Vec, N-Ne
4	CVCX2 = Indeterminate; CVCX3 = Non-COVID-19, NEWS=National Early Warning Score, SpO2=Oxygen Saturations, CRP=C-Reactive Protein, Y=Yes, N=No, ND=Not Done
5	ND-NOT DOILE
6	
7	
8	
9	
10 11	
11 12	
12	
14	
15	
16	
17	
18	
19	
20	
21	
22 23	
24	
25	
26	
27	
28	
29	
30	
31 32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42 43	
43 44	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
45	

Supplementary Table 4: Cross tabulation of results of the triage algorithm with and without FebriDx as well as the results of FebriDx within the possible COVID-19 group compared to a SARS-CoV-2 RT-PCR reference standard after excluding patients arriving before 08/10/2020.

		SARS	S-CoV-2 RT-PCR		
А		Positive	Negative	Total	
Clinical criteria alone	Likely or Possible COVID-19	82	422	504	PPV: 16.3% (95% CI: 13.3 – 19.8)
(without FebriDx) (n=1085)	Unlikely COVID-19	0	581	581	NPV: 100% (95% CI: X – X)
	Total	82	1003	1085	
		Sensitivity	Specificity		
		100%	57.9%		
		(95% CI: X – X)	(95% CI: 54.8 – 61.0)		
		SAR	S-CoV-2 RT-PCR		
В		Positive	Negative	Total	
FebriDx alone in the possible	FebriDx Positive	24	39	63	PPV: 38% (95% CI: 27 – 51)
COVID-19 group with FebriDx done.	FebriDx Negative	2	245	247	NPV: 99.2% (95% CI: 96.8 – 99.8)
(n=310)	Total	26	284	310	
	<u>.</u>	Sensitivity 92.3% (95% CI: 73.8 – 98.1)	Specificity 86.3% (95% CI: 81.7 – 89.8)		
		SARS	S-CoV-2 RT-PCR		
С		Positive	Negative	Total	

С		Positive	Negative	Total	
	Triago				PPV:
Triage	Triage Positive	80	177	257	31%
Algorithm	1 obitive				(95% CI: 26 - 37)
using clinical criteria and	Triage Negative			828	NPV:
FebriDx		2	826		99.8%
(n=1085)					(95% CI: 99.0 - 99.9)
	Total	82	1003	1085	
		Sensitivity	Specificity		
		97.6%	82.4%		
		(95% CI: 91 - 99)	(95% CI: 79.9 – 84.6)		

Measures of Diagnostic Performance are presented for the triage algorithm for the detection of COVID-19: 3A) Using clinical criteria alone without FebriDx, where subjects are classified as positive or negative based on clinical criteria shown in Table 1. Subjects were 'positive' if they were assigned as likely or possible COVID-19 based on clinical criteria alone. 3B) Using the FebriDx assay alone within the possible COVID-19 group receiving a FebriDx test. Subjects are classed as FebriDx positive or negative based on the FebriDx test only. 3C) Using clinical criteria supported by the FebriDx assay. Subjects were classed as Triage positive or negative based on their flow through the algorithm as shown in figure 1. Patients were Triage positive if they were triaged as likely COVID-19 or possible COVID-19 with a negative FebriDx result. PAU PPV = Positive Predictive Value, NPV = Negative Predictive Value, CI = Confidence Interval

Supplementary Table 5: Actual bed allocation to isolation rooms or COVID-19 cohorts in SARS-CoV-2 RT-PCR positive patients, and those requiring isolation following triage.

	SARS-CoV- 2 RT-PCR Positive (n=136)	Triage Positive (n=574)	Likely (n=175)	Possible, FebriDx Positive (n=132)	Possible, FebriDx Not Done (n=267)
'Non-COVID' Ward	7	68	5	4	58
Isolation Room	112	477	152	122	203
COVID-19 Cohort Ward	17	29	18	6	6
% Isolated	95	88.2	97	97	78

Table 4 footnotes: Actual patient movement from the emergency department extracted from the hospital's bed management system.

## **STARD 2015**

#### AIM

STARD stands for "Standards for Reporting Diagnostic accuracy studies". This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

#### EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test.** A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

#### DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select

items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <u>http://www.equator-network.org/reporting-guidelines/stard.</u>

Section & Topic	No	Item	Reported on page #
TITLE OR			1
ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of	1
		accuracy	
		(such as sensitivity, specificity, predictive values, or AUC)	
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions	2
		(for specific guidance, see STARD for Abstracts)	
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of	4
		the index test	
	4	Study objectives and hypotheses	5
METHODS			
Study design	5	Whether data collection was planned before the index test and reference	5
		standard	
		were performed (prospective study) or after (retrospective study)	
Participants	6	Eligibility criteria	5, table 1 (page
			12)
	7	On what basis potentially eligible participants were identified	5
		(such as symptoms, results from previous tests, inclusion in registry)	
	8	Where and when potentially eligible participants were identified (setting,	5
		location and dates)	
	9	Whether participants formed a consecutive, random or convenience series	5
Test methods	10a	Index test, in sufficient detail to allow replication	6
	10b	Reference standard, in sufficient detail to allow replication	6
	11	Rationale for choosing the reference standard (if alternatives exist)	NA
	12a	Definition of and rationale for test positivity cut-offs or result categories	5
		of the index test, distinguishing pre-specified from exploratory	
	12b	Definition of and rationale for test positivity cut-offs or result categories	NA
		of the reference standard, distinguishing pre-specified from exploratory	
	13a	Whether clinical information and reference standard results were available	6
		to the performers/readers of the index test	
	13b	Whether clinical information and index test results were available	6
		to the assessors of the reference standard	
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	7
	15	How indeterminate index test or reference standard results were handled	7
	16	How missing data on the index test and reference standard were handled	7
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified	NA
		from exploratory	
	18	Intended sample size and how it was determined	7
RESULTS			
Participants	19	Flow of participants, using a diagram	Figure 1 (page 17
	20	Baseline demographic and clinical characteristics of participants	Table 2 (page 18)

	21a	Distribution of severity of disease in those with the target condition	Table 2 (page 18)
	21b	Distribution of alternative diagnoses in those without the target condition	NA
	22	Time interval and any clinical interventions between index test and reference standard	6
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 3 (page 20 and Supplementary Table 4
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Table 3 (page 20
	25	Any adverse events from performing the index test or the reference standard	NA
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	11
	27	Implications for practice, including the intended use and clinical role of the index test	12
OTHER INFORMATION			
	28	Registration number and name of registry	NA
	29	Where the full study protocol can be accessed	NA
	30	Sources of funding and other support; role of funders	12

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	2
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	4
		reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of	5
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	5 and
		participants. Describe methods of follow-up	Table
		(b) For matched studies, give matching criteria and number of exposed and	-
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	6
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	7
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	7
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	7
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA
		( <u>e</u> ) Describe any sensitivity analyses	7
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	Figu
		potentially eligible, examined for eligibility, confirmed eligible, included in the	1
		study, completing follow-up, and analysed	1
		(b) Give reasons for non-participation at each stage	Figur
		(c) Consider use of a flow diagram	1
		(c) consider use of a now diagram	Figu
	4 4 16		1 Table
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	2

		(b) Indicate number of participants with missing data for each variable of interest	Tabl 2
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	9

to beet teries only

Main	16	( <i>a</i> )	Give unadjusted estimates and, if applicable, confounder-adjusted	d estimates and	8			
results		their precision (eg, 95% confidence interval). Make clear which confounders were						
		adjusted for and why they were included						
		( <i>b</i> )	Report category boundaries when continuous variables were cate	egorized	Table 2			
		( <i>c</i> )	If relevant, consider translating estimates of relative risk into abs	olute risk for a				
		mea	aningful time period		NA			
	Other analyses	17	Report other analyses done-eg analyses of subgroups and	Supplementary				
			interactions, and sensitivity analyses	table 3				
	Discussion				_			
	Key results	18	Summarise key results with reference to study objectives	Table 3	_			
	Limitations	19	Discuss limitations of the study, taking into account sources	11	-			
			of potential bias or imprecision. Discuss both direction and					
			magnitude of any potential bias					
	Interpretation	20	Give a cautious overall interpretation of results considering	12	-			
			objectives, limitations, multiplicity of analyses, results from					
			similar studies, and other relevant evidence					
	Generalisability	21	Discuss the generalisability (external validity) of the study	12	-			
			results					
	Other information							
	Funding	22	Give the source of funding and the role of the funders for the	13	_			
			present study and, if applicable, for the original study on					
			which the present article is based					

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.